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Glucocorticoid excess causes obesity, dyslipidaemia, insulin resistance and
hypertension as seen in Cushing's syndrome. In idiopathic obesity, circulating
Cortisol levels are not elevated but Cortisol metabolism is altered. lip-
hydroxysteroid dehydrogenase type 1 (11HSD1) is an intracellular enzyme that
converts inactive cortisone into active Cortisol. Data from animals suggests that
elevated adipose 11HSD1 may generate more glucocorticoid within adipose tissue
and be an important mediator of obesity and the associated metabolic consequences
(diabetes, dyslipidaemia and hypertension). This thesis addresses whether adipose
IIHSD1 is elevated in human obesity, investigates if this occurs through altered
transcription, and assesses the downstream impact (changes in downstream target
genes and metabolic outcomes). Regulation of 11HSD1 mRNA in animal and cell
models (eg by high fat feeding, insulin, and PPAR agonists), and putative control of
enzyme direction by NADPH generation (via hexose-6-phosphate dehydrogenase),
suggest a dynamic role for 11HSD1 in the adaptive response of adipose to altered
nutrition. The importance of these potential regulators in lean and obese humans is
also addressed in this thesis.
In subcutaneous adipose biopsies from male and female healthy volunteers
from Finland (n=19), Sweden (n=27) and USA (n=35) 11HSD1 activity (in vitro
conversion of Cortisol to cortisone in presence of NADP) and mRNA (by real time
PCR) was increased in association with generalised and 'central' obesity (which is
most strongly associated with increased cardiovascular risk), and predicted insulin
resistance. However, glucocorticoid receptor mRNA was negatively associated with
obesity and insulin resistance. Adipose mRNAs for a number of key functional
adipose targets (adiponectin, LPL, HSL, angiotensinogen, resistin, aromatase,
PPARy) were not significantly associated with 11HSD1 expression or activity.
To investigate 11HSD1 regulation, a series of randomised controlled studies
in vivo in healthy male volunteers were performed to assess the regulatory effects of
insulin (euglycaemic clamp) or lipid (20% Intralipid iv) over 3.5 hours and PPAR
agonists (rosiglitazone or fenofibrate for 7 d). Deuterated-cortisol tracer with GCMS
analysis was used to measure whole body Cortisol turnover and urinary metabolite
excretion, and intra adipose microdialysis was used to assess in vivo s.c. adipose
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11HSD1 activity and directionality. Hyperinsulinaemia increased the rate of
appearance of 9,12,12-[2H]3-cortisol in plasma, indicating increased regeneration of
Cortisol by 11HSD1. Within adipose tissue, the predominant reaction was conversion
of cortisone to Cortisol rather than Cortisol to cortisone; both activities fell during the
first hour of hyperinsulinaemia but subsequently increased. Intralipid infusion had no
significant effects on deuterated Cortisol metabolism, but increased intra-adipose
conversion of cortisone to Cortisol. The PPARy agonist rosiglitazone lowered adipose
11HSD1 reductase activity. The PPARa agonist fenofibrate had no effect on adipose
11HSD1 activity although urinary ratios of Cortisol/ cortisone metabolites and
endogenous Cortisol clearance were reduced. These findings may be suggestive of
decreased liver 5alpha-reductase activity. There were no significant changes in
plasma tracer kinetics with PPAR agonists.
In addition to altered glucocorticoid metabolism, changes in sex steroid
metabolizing enzymes dictating oestrogen (aromatase) and androgen (AKR1C2/3)
action were found to be associated with fat distribution in s.c biopsies from Swedish
(n=27) and Finnish (n=19) volunteers. Further studies to determine the functional
relevance of these associations are planned.
These studies implicate dysregulation of 11HSD1 transcription in the
pathogenesis of human obesity and the metabolic syndrome although the
downstream impact of enzyme dysregulation remains unclear. They also suggest that
11HSD1 is involved in the adaptive response to nutrition, and that alteration in tissue
glucocorticoids may contribute to the therapeutic action of PPAR agonists. This
understanding of enzyme regulation in humans will allow further studies to dissect
the basis of dysregulation in obesity. Inhibition of adipose 11HSD1 remains an
intriguing target for the treatment of obesity and its metabolic complications but its





1.1 Obesity and the Metabolic Syndrome
This thesis will examine the role of steroid action in obesity and its metabolic
consequences, focusing primarily on the actions of glucocorticoids within adipose.
Obesity is set to become the biggest cause of preventable death in the US, and may
be the greatest health threat currently facing the western world. The United States are
the world leaders with over 50% of the population defined as overweight (Mokdad et
al 1999). Scotland is renowned for its poor diet and consequently rates of obesity and
cardiovascular disease are some of the worst in Europe. In 1998 nearly 8% of boys
and 7% of girls were obese and 62% of men and 54% of women in Scotland were
either overweight or obese (Scottish health survey). Childhood obesity has increased
approximately seven fold in the last 30 years with associated increases in type 2
diabetes and other complications (Ebbeling et al 2002). Industrialization,
urbanization, economic development and market globalisation have resulted in a
more sedentary lifestyle and increased refined carbohydrate and fat in the diet.
Genetic factors undoubtedly alter the propensity to obesity (Speakman 2004),
although monogenic causes of obesity are rare (O'Rahilly et al 2003). The health
risks associated with obesity are wide ranging, but include respiratory disease,
osteoarthritis, sleep apnoea, cancer, diabetes mellitus and notably cardiovascular and
cerebrovascular disease (Fontaine et al 2003). The increased propensity to
atheromatous disease is thought to be due to the associated 'metabolic syndrome' or
'syndrome x', defined as the triad of hypertension, insulin resistance and
dyslipidaemia (Reaven 1988). Central, as apposed to peripheral or 'gynoid' obesity is
particularly associated with increased atherogenic risk (Despres et al 1990).
The exact mechanisms linking obesity and the metabolic syndrome are not
fully understood but the role of the adipocyte is emerging as an important one.
Adipose tissue produces many metabolically active factors and, although previously
considered a benign energy storage organ, should now be considered an endocrine
organ in its own right. Adipose tissue metabolism is altered in obesity and may be an
important mediator of the associated dysmetabolic phenotype.
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1.2 Adipose as an Endocrine Organ
Over recent years, adipose tissue has evoked new interest, emerging as a key
metabolic tissue. This was fuelled by the discovery of Leptin in 1994 (Zhang et al
1994), a circulating factor secreted from fat cells shown initially to regulate appetite,
and subsequently to have effects on many other aspects of physiology including bone
mass, reproductive function and cardiovascular disease (Caro et al 1996). Since then,
a spectrum of other 'adipokines' have been discovered including adiponectin,
resistin, adiponutrin, acylation stimulating protein (ASP), plasminogen activator
inhibitor (PAI-1), angiotensin II, and soluble preadipocyte factor (Cianflone et al
1999;Steppan et al 2001;Stefan & Stumvoll 2002;Diez & Iglesias 2003;Weigle et al
2003;Polson & Thompson 2003;Lee et al 2003). Adiponectin (also called Acrp30,
GBP-28, and apMl) is a novel adipose specific protein with a structure similar to
collagen VIII and X and complement factor Clq. Circulating levels of adiponectin
have been inversely associated with the degree of adiposity, plasma glucose, insulin
and triglyceride levels and positively related to insulin sensitivity both in healthy
subjects and diabetic patients. This may be mediated in part through increasing tissue
fatty acid oxidation (Diez & Iglesias 2003). Resistin is another novel signaling
molecule, released from fat cells, and thought to mediate insulin resistance. In mice,
administration of anti-resistin antibody improves blood sugar and insulin action and
treatment with recombinant resistin impairs glucose tolerance and insulin action
(Steppan et al 2001). The important of resistin in human disease however is not yet
fully understood. Estrogens (Simpson 2000b), glucocorticoids and inflammatory
cytokines are also generated within adipose tissue, and may be elevated in obesity.
Insulin resistance may also be controlled by the action of free fatty acids on the liver,
draining from visceral fat through the portal circulation. Increased liberation and
action of free fatty acids from adipose in obesity, under control of lipases (HSL and
LPL) and nuclear receptors (PPAR-y), may therefore be important regulators of
insulin resistance in obesity.
1.3 The Role of Inflammation
The role of 'inflammation' in obesity and cardiovascular disease is
particularly topical. Obesity is associated with elevated levels of circulating
24
inflammatory cytokines (Xydakis et al 2004). Further, increasing inflammatory
markers predict the metabolic features (insulin resistance, hypertension and
dyslipidaemia) and are independently associated with cardiovascular and
cerebrovascular endpoints (Ridker et al 2003;Ridker & Morrow 2003). Inflammatory
cytokines including TNF-a, IL-1 and IL-6 can be generated within adipose tissue
although whether these originate from infiltrating immune cells or adipocytes
themselves remains controversial. Circulating inflammatory cytokines may regulate
pathophysiological processes both locally, e.g. within adipose, and at distal sites such
as the endothelium. The hypothalamic pituitary axis (HPA) can also be stimulated by
inflammatory cytokines and resultant hypercortisolaemia may be important for
resolution of inflammation (Mulla & Buckingham 1999).
1.4 The Neuroendocrine control of Body Weight
Over the past decade there has also been a tremendous increase in the
understanding of the molecular endocrine and neural mechanisms underlying control
of body weight. Regulation of appetite, feeding and energy balance is complex but in
part mediated by circulating hormones and direct neural signals from peripheral
tissues, such as adipose and gut. Distension of the stomach and small bowel, insulin
release and specific hormonal signals all feedback information to the CNS about
feeding. Peptide-YY (PYY) and glucagon-like peptide 1 are hormones co-secreted
from the intestine into the circulation following food intake and acutely inhibit
appetite (Schwartz et al 2000;Spiegelman & Flier 2001;Saper et al 2002). Ghrelin is
thought to perform the opposite role, being released from the stomach and
gastrointestinal tract as a 'hunger' signal which is suppressed by food intake
(Horvath et al 2001). Adipokines such as leptin provide longer term information
from fat tissue about energy balance. The arcuate nuclei and dorsomedial/
paraventricular nuclei in the hypothalamus regulate feeding behaviour, metabolic
rate and energy expenditure in response to these peripheral signals (Zigman &
Elmquist 2003). Obesity may be associated with dysfunctional neuroendocrine
signalling, the most recognised phenomenon being leptin resistance.
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1.5 Glucocorticoids in Obesity and the Metabolic Syndrome
This thesis will focus on the role of glucocorticoid metabolism in obesity.
Glucocorticoids mediate their tissue effects by activation of intracellular receptors.
Cortisol, the principal active glucocorticoid in man, is an important regulator of
many physiological pathways, particularly at times of stress or illness. Excessive
glucocorticoid exposure either as a result of endogenous overproduction (i.e.
Cushing's syndrome) or exogenous administration (in the treatment of inflammatory
diseases) results in increased central adiposity, insulin resistance, dyslipidaemia and
hypertension. Idiopathic obesity is also associated with these dysmetabolic features,
defined as 'the metabolic syndrome'. The phenotype of Cushing's syndrome is
reversible upon removal of glucocorticoid excess. It has been proposed that subjects
with obesity and the metabolic syndrome have increased glucocorticoid receptor
activation, and further that they may be susceptible to therapeutic manipulation of
tissue glucocorticoid exposure. In idiopathic obesity, circulating plasma Cortisol
levels are not elevated, but dysregulation of peripheral Cortisol metabolism and
excretion and alterations in glucocorticoid feedback (through the HPA axis), may
explain the phenotypic similarities with Cushing's syndrome.
1.6 The HPA axis and Cortisol Clearance in Obesity
Idiopathic obesity is associated with increased Cortisol secretion indicating
activation of the HPA axis. This has variably been attributed to increased long term
stress (Schwartz et al 2000) and alterations in HPA axis feedback (Ljung et al
1996;Jessop et al 2001 ;Di Blasio et al 2003). The HPA axis in obesity is hyper-
responsive when stimulated e.g. by acute stress, CRH/ AVP, hypoglycaemia, or a
standard meal test (Pasquali et al 1993;Vicennati & Pasquali 2000;0'Rahilly et al
2003). Further, obesity is associated with resistance to glucocorticoid feedback
(Jessop et al 2001;Ljung et al 2002) an effect which may be mediated via altered
sensitivity of glucocorticoid or mineralocorticoid receptors. Some studies suggest
that individuals with common glucocorticoid receptor polymorphisms demonstrate
HPA axis abnormalities in addition to a peripheral phenotype of increased adiposity,
insulin resistance and hypertension (Bjorntorp et al 1999;Rosmond et al 2000;Van
Rossum et al 2002;Ljung et al 2002;Di Blasio et al 2003).
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The diurnal rhythm of plasma Cortisol is however lost in obesity such that
plasma Cortisol is higher than in lean subjects during the evening nadir but lower
than expected during the morning peak (Ljung et al 1996;Rosmond et al
1998;Walker et al 2000). The combination of increased total Cortisol secretion with
lower plasma Cortisol levels during peak secretion suggests that peripheral Cortisol
clearance is increased in obesity. Over 20 years ago it was observed that obesity is
associated with increased Cortisol production and clearance rates (Lottenberg et al
1998). Increased glucocorticoid clearance could itself reduce plasma levels and lead
to compensatory HPA axis activation.
The enzymes, which may be responsible for increased glucocorticoid
clearance in obesity, were identified by analysis of Cortisol metabolites in the urine.
Increased relative excretion of A-ring reduced metabolites of Cortisol was observed
(Andrew et al 1998;Fraser et al 1999), attributable to activation of the hepatic A-ring
reductase enzymes. These enzymes perform the rate limiting step in the reduction of
glucocorticoids (Cortisol in man, corticosterone in rats and mice) to tetra-hydro
products which are ultimately excreted in the urine (figure 1.1). The A-ring
reductase enzymes (namely 5a- and 5P-reductase) are activated in both animal
(Livingstone et al 2000) and human obesity (Andrew et al 1998;Fraser et al 1999).
The underlying cause of increased enzyme activity is largely unknown but these
enzymes may be regulated by nutritional factors such as insulin and lipids, and
substrate availability. 5P-Reductase is also a key enzyme involved in cholesterol
metabolism and bile acid biosynthesis, which may compete with glucocorticoids.
Despite strong evidence that dysregulation of the HPA axis and
glucocorticoid clearance pathways exists in obesity, from first principles
manipulation of these pathways for therapeutic benefit is unlikely to be fruitful.
Inhibition of Cortisol biosynthesis is potentially hazardous due to risk of Addisonian
crisis. Further, circulating Cortisol levels are already low and any attempt to increase
clearance is likely to result in further HPA activation and Cortisol and adrenal
androgen production. Tissue-specific manipulation of glucocorticoid effects may
therefore be a more useful strategy. The 11HSD type 1 enzyme regulates the balance
of active and inactive tissue glucocorticoid levels and is dysregulated in obesity; as










11HSD1 interconverts Cortisol and inactive cortisone. The A-ring
Reductases (5a and 5P-Reductase) convert Cortisol and cortisone ultimately
to tetra-hydro products within the liver. These are ultimately conjugated and
excreted in the urine. THF= tetrahydrocortisol, THE= tetrahydrocortisone
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1.7 The lip-Hydroxysteroid Dehydrogenases (llHSDs)
Until relatively recently, tissue glucocorticoid concentrations were thought to
be determined exclusively by plasma levels of glucocorticoids and binding proteins,
and tissue responses controlled by availability of glucocorticoid receptors. Other
hormones, however, also regulate tissue responses through pre-receptor enzymes, co-
expressed with the intracellular receptor, which metabolise ligand and control
receptor access (e.g. 5a-reductase type 2 for androgens and 5'-monodeiodinase for
thyroxine)(Stewart & Sheppard 1992). It is now known that the 1 ip-hydroxysteroid
dehydrogenase enzymes perform this role for glucocorticoid and mineralocorticoid
receptors.
The 11 P-hydroxysteroid dehydrogenases (1 lHSDs) were discovered some 50
years ago (Amelung et al 1953), yet their potential as therapeutic targets is only now
emerging. These microsomal enzymes interconvert active and inactive
glucocorticoids, thus acting as gate keepers for intracellular receptors (White et al
1997;Stewart & Krozowski 1999;Seckl & Walker 2001). By controlling substrate
availability (Cortisol in humans, corticosterone in rats and mice), they mediate tissue
specific glucocorticoid receptor activation, irrespective of circulating plasma Cortisol
levels. Glucocorticoids are important regulators of patho-physiological processes in
many tissues, therefore pharmacological manipulation of these novel enzymes may
have wide ranging therapeutic benefits.
There are two 11HSD isozymes (figure 1.2). The type 2 enzyme is an
exclusive NAD dependent dehydrogenase, converting active Cortisol to inactive
cortisone. Its main role is in aldosterone sensitive target tissues (kidney, colon,
salivary glands and placenta) as described by Stewart and Edwards and others in the
1980s (Funder et al 1988;Edwards et al 1988). Cortisol circulates in several-fold
higher plasma concentrations than aldosterone but both have similar affinity for the
non-selective mineralocorticoid receptor. By inactivating Cortisol, 11HSD2 prevents
flooding of mineralocorticoid receptors leaving free access for aldosterone. This is
particularly important in the distal nephron. 11HSD2 was cloned in 1994 (Albiston et
al 1994) and since 1995 the rare syndrome of apparent mineralocorticoid excess
(SAME) (characterised by hypertension, hypokalaemia and fluid retention due to
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e.g. Liver/ Adipose e.g. Kidney
Figure 1.2
Cortisol/ Cortisone generation in MR/ GR Dependent Tissues.
11HSD1 is found in GR sensitive tissues where regeneration of Cortisol
from cortisone results in activation of GR. 11HSD2 is found in MR
sensitive tissues where conversion of Cortisol to inactive cortisone prevents
illicit occupation of MR receptors. 11HSD1= 1 lbeta-hydroxysteroid
dehydrogenase type 1, 11HSD2= 1 lbeta-hydroxysteroid dehydrogenase
type 2, F= Cortisol, E= cortisone, GR= glucocorticoid receptor, MR=
mineralocorticoid receptor.
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illicit occupation of mineralocorticoid receptors by Cortisol) has been attributed to
mutations in the HSD11B2 gene (Dave-Sharma et al 1998).
11HSD type 1 was poorly understood during these early years, but is now
recognized as an abundant and physiologically important enzyme. Mammalian
11HSD1 was first cloned from rat liver cDNA in 1989 (Agarwal et al 1989). Later a
library derived from human testis was probed using the rat lipHSD and further
clones identified. Hybridization of the human 11B-HSD1 cDNA to a human-hamster
hybrid panel localized the single HSD11 gene to chromosome 1 (subsequently
refined to chromosome lq32.2-41) (Tannin et al 1991). The human gene has been
designated HSD11B1 and consists of six exons and five introns.
11HSD1 belongs to the short chain dehydrogenases/reductases family
(SDRs), a well established enzyme family of oxidoreductases. This enzyme is
microsomal (Ozols 1995), and activity in early purification studies showed bi-
directionality in vitro, but with predominant and more stable dehydrogenase activity.
Further studies, however, revealed 11B-HSD1 to act in vivo (and in intact cell
systems) as a predominant NADPH dependent reductase (figure 1.3). Thus, lip~
HSD1 performs the opposite role to 11HSD2, i.e. generating Cortisol from inactive
cortisone (Walker et al 1992;Low et al 1994;Bujalska et al 1997;Katz et al
1999;Seckl & Walker 2001). This striking change in directionality between intact
cells and homogenates seems to reflect the specific intracellular localization of 11B-
HSD1 within the lumen of the endoplasmic reticulum (ER), where neighboring
enzymes may be powerful generators of the reduced cosubstrate NADP phosphate
(NADPH)(Tomlinson et al 2004b).
11HSD1 is found in many tissues including liver, adipose, gonads, brain and
vasculature. These tissues are abundant in glucocorticoid rather than
mineralocorticoid receptors. If 11HSD1 modulates access of ligand to glucocorticoid
receptors in these tissues, then it may have implications in many common diseases
which share features of Cushing's syndrome, including idiopathic obesity, diabetes




















Reactions catalysed by lip-hydroxysteroid dehydrogenase type 1 in
humans.
Inactive and active glucocorticoids are interconverted by 1 lketo-
reductase and 11 P-dehydrogenase activities. In vivo, Hexose-6-Phosphate
Dehydrogenase (H6PDH) generates NADPH which drives reductase
activity. Glucose-6-phosphate is the main substrate for H6PDH.
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1.8 11HSD1 in the Pathophysiology of Obesity
1.8.1 Lessons from transgenesis
The potential importance of 11HSD1 in obesity has emerged from in vitro
studies, in vivo animal models, human studies and perhaps most persuasively by the
development of transgenic mice. These mouse models have given insight into the
expected human phenotypes resulting from changes in 11HSD1 activity. Striking
metabolic consequences have been observed by altering 11HSD1 expression.
Adipose specific over-expression of 11HSD1 (under an AP2 promoter) produces a
phenotype analogous to the metabolic syndrome (with central obesity, hypertension,
insulin resistance and dyslipidaemia) (Masuzaki et al 2001;Masuzaki et al 2003).
This is associated with high intra-adipose corticosterone, high levels of plasma
leptin, tumour necrosis factor (TNF)-alpha, and adipose lipoprotein lipase (LPL)
mRNA. Cortisol is elevated in the portal vein but normal in the peripheral circulation
because of reduced adrenal production. Levels of adipose uncoupling protein-1
(UCP-1) mRNA are low, portal flow of triglycerides is increased and
angiotensinogen production is elevated which may explain the associated
hypertension (Masuzaki et al 2003).
Knockout mice, homozygous for a deleted 11HSD1 allele, are conversely
protected from the metabolic consequences of obesity (Kotelevtsev et al
1997;Morton et al 2001). They have lower intra-cellular corticosterone levels despite
mildly elevated circulating levels (Harris et al 2001;Yau et al 2001), a favourable
lipid profile (lower serum triglycerides, and high HDL cholesterol) and resist
hyperglycaemia induced by stress and during high fat feeding. Changes in
glucocorticoid dependent gene expression are also seen in the liver, with decreased
gluconeogenic enzymes (notably PEPCK) and increased enzymes of lipid oxidation.
When rederived against an obesity prone genetic background (C57/B16), 11HSD1 -/-
mice are further protected from weight gain on a high fat diet (Morton et al 2004b).
Overexpression of 11HSD1 in the liver, alternatively, under an ApoE
promoter results in fatty liver, dyslipidaemia, mild insulin resistance and
hypertension which again is thought to be mediated by increased angiotensinogen
expression. These animals do not however demonstrate increased adiposity (Paterson
et al 2004).
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The striking phenotype of these transgenic models suggests that 11HSD1 can
be a potent pathophysiological force in the development of the metabolic syndrome,
and further that there could be wide-ranging therapeutic benefits from 11HSD1
inhibition, including improvements in dyslipidaemia, hypertension, insulin resistance
and potentially limitation of weight gain in obesity susceptible individuals (figure
1.4).
1.8.2 Urinary Cortisol metabolite profiles
Transgenic models may help to predict human phenotypes, but clinical
studies are required to assess in vivo 11HSD1 activity in human obesity. Assessment
of 11HSD1 in humans is difficult. Conventionally, urine is examined by mass
spectrometry to assess the ratios of Cortisol: cortisone metabolites; an elevated ratio
may be taken to indicate increased regeneration of Cortisol from cortisone by
11HSD1. However, these measurements gave conflicting results, showing variably
increased (Andrew et al 1998;Rask et al 2002;Tiosano et al 2003), decreased
(Stewart et al 1999;Rask et al 2001), or unchanged (Fraser et al 1999;Reynolds et al
2001) Cortisol:cortisone metabolite ratio in relation to parameters of obesity. This
suggests that there may be unmeasured confounding influences determining the
Cortisol:cortisone metabolite ratio, over and above any influence of 11HSD1. Other
enzymes such as 11HSD2 and the A-ring reductases (5a- and 5P-reductase) can
affect Cortisol: cortisone metabolite ratios. A recent study illustrates the importance
of these enzymes, since in a group of patients with careful characterization of body
fat distribution the Cortisol:cortisone urinary metabolite ratio was shown to be more
closely associated with accumulation of fat in the liver rather than in adipose tissue;
further, the ratio was unrelated to measurements of 11HSD1 in adipose biopsies or to
conversion of cortisone to Cortisol in vivo, and appeared to reflect mainly an increase
in 5P-reductase (Westerbacka et al 2003). Because of these difficulties, urinary
measurements should not be used in isolation to assess 11HSD1 activity.
Stable isotope tracers, which allow distinction between Cortisol generated
from cortisone from that directly secreted by the adrenal or infused, may allow
dissection of whole-body 11HSD1 activity specifically but these are laborious
techniques (Andrew et al 2002). Moreover, it appears that changes in 11HSD1 in
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A model of the metabolic syndrome mediated by elevated adipose
11(3-HSD type 1. Increased adipose 1 lp-HSDl in obesity may be
secondary to dysregulation by factors described above. Increased Cortisol
generation will result in activation of GR and downstream genes
transcription. This may lead to a pro-atherogenic dysmetabolic
phenotype resulting in increased cardiovascular disease
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obesity are tissue-specific, so that measurement in isolated circulation (Basu et al
2004) or biopsied tissues may still be essential to understand dysregulation of
11HSD1 in human disease.
1.8.3 Defining tissue-specific changes
Investigation of the tissue-specific dysregulation of 11HSD1 in obesity began
with studies of obesity prone, insulin resistant animal models (e.g. obese Zucker
rats). These animals have tissue-specific alterations in 11HSD1, notably increased
11HSD1 in visceral fat and reduced 11HSD1 in hepatic tissue (Livingstone et al
2000). Reduced hepatic (Liu et al 2003) and increased adipose (Masuzaki et al 2001)
I1HSD1 has also been reported in ob/ob mice. Similar tissue-specific dysregulation
was subsequently demonstrated in human studies. Hepatic 11HSD1 activity is
reduced in obesity, as judged by impaired conversion of cortisone to Cortisol on first
pass metabolism through the liver (Stewart et al 1999). This is accompanied by
increased 11HSD1 activity in homogenates of sub-cutaneous adipose tissue (Rask et
al 2001;Rask et al 2002).
On beginning the work for this thesis, a key question remained concerning
whether adipose 11HSD1 upregulation is transcriptional, and the extent to which
upregulation in obesity influences intra-adipose Cortisol levels and the metabolic
consequences of obesity. The model suggested by the Ap2-11HSD1 overexpressing
animal is intriguing, but whether this models idiopathic human obesity remains
uncertain (Masuzaki et al 2001).
1.8.4 11HSD1 in other insulin resistant syndromes
In addition to dysregulation in patients with idiopathic obesity, it is proposed
that the central adiposity of growth hormone (GH) deficient patients and
hypothalamic obesity may also be associated with changes in Cortisol metabolism
and 11HSD1 activation. 11HSD1 is inhibited by GH and IGF-1 in adipose tissue in
vitro (Moore et al 1999;Tomlinson et al 2001). In vivo human studies in
hypopituitarism and acromegaly suggest that this effect is important (Moore et al
1999;Trainer et al 2001) and have also shown lowering of Cortisol:cortisone
metabolite ratios by GH therapy in hypopituitary patients (Weaver et al 1994) and in
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patients with idiopathic obesity (Tomlinson et al 2003). The latter, however,
occurred without any changes in fat mass. As in studies of idiopathic obesity, the
difficulty is in the interpretation of urinary Cortisol:cortisone metabolite ratios as a
reflection of potentially tissue-specific changes.
Abnormalities in Cortisol metabolism also exist in patients with type 2
diabetes compared to matched controls, over and above any effect of obesity
(Andrew et al 2002;Valsamakis et al 2004). These abnormalities include enhanced
central and peripheral sensitivity to glucocorticoids and slight impairment of
11HSD1 activity in the liver, but no difference in adipose 11HSD1.
In polycystic ovary syndrome, urinary Cortisol:cortisone metabolite ratios
have been reported to be unchanged (Stewart et al 1990) or increased (Rodin et al
1994), but the confounding effect of obesity may account for this.
1.8.5 11HSD1 Genetics
Only a handful of patients with apparent congenital cortisone reductase
deficiency (ACRD) exist. These individuals have a defect in cortisone to Cortisol
conversion that is now thought to be due to combined single allele mutations in
11HSD1 and hexose-6-phosphate dehydrogenase (see also section 1.9.3) (Draper et
al 2003). No widespread common functional mutations in the coding region of the
type 1 isozyme have been found, however, phenotype-genotype relationships exist
with specific 11HSD1 intronic polymorphisms (Draper et al 2002), and
polymorphisms in the 5' upstream sequence (Nair et al 2004;Franks et al 2004). The
intronic polymorphisms described by Draper et al were associated with obesity
related parameters such as waist:hip ratios and hypertension, whereas upstream SNPs
in Pima Indians predicted type 2 diabetes, plasma insulin levels and insulin action
independently of obesity, and may occur in areas of transcription factor binding sites.
Many genetic studies are still ongoing and mutations in the promoter region of
11HSD1 are yet to be fully screened. However, given uncertainties over the
specificity of urinary Cortisolicortisone metabolite ratios, linking genotype with
phenotype of altered enzyme activity in vivo will be difficult.
37
1.9 Regulation of Cortisol Metabolism in Obesity
11HSD1 is a highly transcriptionally regulated gene with many transcription
factor binding sites in its promoter region (including CEBP and HNF, SF1, API and
AP2) (Williams et al 2000). Various regulators have been identified in vitro
including glucocorticoids, thyroid hormones, sex steroids, insulin, IGF-1, lipids,
leptin, GH, PPAR ligands and cytokines, many of which are altered in obesity
(Bujalska et al 1997;Berger et al 2001;Tomlinson et al 2001 ;Liu et al 2003) (figure
1.4). Here, I will focus on the role of nutritional factors, inflammation, and the
potential role of cofactor generation on the regulation of 11HSD1 in human obesity.
1.9.1 Nutritional Regulation
The HPA axis has previously been shown to respond to FFAs, insulin, leptin
and high fat feeding. Further studies now suggest that these effects may be secondary
to changes in peripheral Cortisol metabolism (Dallman et al 1993) and a potential key
role for 11HSD1 in the adaptive response to nutritional signals is emerging. 11HSD1
mRNA is regulated in vitro by insulin (Napolitano et al 1998;Handoko et al
2000;Tomlinson et al 2001), and PPAR/ FXR agonists (Berger et al 2001;Stulnig et
al 2002). Further, enzyme direction may potentially be controlled by change in
glucose flux, as NADPH generation through hexose-6-phosphate dehydrogenase
requires glucose-6-phospate as substrate (see section 1.9.3) (Draper et al
2003;Banhegyi et al 2004). In rodents, high fat feeding potently down-regulates
hepatic and adipose 11HSD1. Further, 11HSD1 knock-out models resist diet induced
visceral obesity (Morton et al 2004a).
Studies in humans have been limited. Weight loss has been shown to increase
plasma Cortisol/ cortisone ratios and elevate 11HSD1 mRNA in isolated adipocytes
(Tomlinson et al 2004a), although this finding is not universal (Engeli et al 2004).
5% weight loss in obese men induced by starvation or very low calorie diet had
contrasting effects, with only the latter normalising Cortisol clearance but neither
apparently affecting 11HSD1 (Johnstone et al 2004) (measured by urinary ratios).
Whether changes in Cortisol metabolism is due to specific dietary components,
changes in weight or mediated through secondary factors such as insulin is unknown.
Most recently our group has measured adipose 11HSD1 in man using in vivo intra-
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adipose infusion of 3H-cortisone by microdialysis, and shown that hyperinsulinaemia
very acutely down-regulates its conversion to 3H-cortisol by 11HSD1; most
importantly, obese subjects resist this insulin-dependent down-regulation (Sandeep et
al 2005). Dysregulation of adipose 11HSD1 in obesity may therefore potentially be
mediated by altered response to nutritional factors.
1.9.2 Inflammatory Regulation
As described in section 1.3, idiopathic obesity is associated with a relative
'inflammatory state', and increases in plasma markers of inflammation such as CRP,
IL-6, and IL-1 (3 have been shown to predict the risk of progression to type 2 DM, the
risk of subsequent diabetic complications (Streja et al 2003), and to independently
predict cardiovascular disease risk (Ridker et al 2003). Anti-inflammatory agents
including aspirin and salicylate compounds substantially improve insulin sensitivity
in human and animal models (Yuan et al 2001;Hundal et al 2002). This is associated
with altered expression of many adipose gene transcripts mediated through activation
of NFk-B and IKK-P signaling pathways. Further, over-expression of NFk-B in
adipose tissue results in an insulin resistant phenotype, which can be reversed by
salicylate administration (Yuan et al 2001).
Activation of inflammatory pathways may mediate increased tissue Cortisol
generation by 11HSD1 in obesity, and a reduction in 11HSD1 may underlie the
insulin sensitising effects of anti-inflammatory agents. In-vitro studies have shown
that inflammatory cytokines (e.g TNF-a and IL—1) increase tissue 11HSD1 activity
in many cell types in vitro (Handoko et al 2000;Cai et al 2001 ;Tomlinson et al
2001;Cooper et al 2001). In vivo, inflammatory conditions such as FHV
lipodystrophy and TB are associated with increased adipose and hepatic 11HSD1
respectively (Baker et al 2000;Sutinen et al 2004). Further, inflammatory signaling
pathways (e.g. NFk-B) regulate activation of intracellular glucocorticoid receptors
(Widen et al 2003) as seen in inflammatory conditions such as rheumatoid arthritis.
In obesity, activation of both 11HSD1 and GR in adipose tissue and liver by
inflammatory mediators may be detrimental, leading to increased glucocorticoid
signaling resulting in an adverse metabolic (pro-atherogenic) phenotype.
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1.9.3 11HSD1 regulation by cofactor availability
11HSD1 may also be regulated post-transcriptionally. Here the focus of
attention is on the factors determining enzyme directionality. In tissue homogenates
and some cultured cells 11HSD1 is a dehydrogenase, converting Cortisol to cortisone
(Bujalska et al 2002a). The reasons remain unclear, but a recent intriguing hypothesis
has been proposed by Stewart and colleagues that the directionality is determined by
co-factor availability. 11HSD1 relies on NADPH to function as a reductase
(converting inactive 11-keto glucocorticoids to their active 11-hydroxy metabolites)
(figure 1.3). Hexose-6-phosphate dehydrogenase (H6PDH) is closely associated with
11HSD1 on the inner endoplasmic reticulum and controls local NADPH availability
(Stewart & Krozowski 1999). NADPH generated in this manner may be important
for maintaining the predominant reductase activity seen in intact cells in vivo which
is lost post homogenization or in culture. Further, alterations in H6PDH expression
may be associated with change in 11HSD1 activity and enzyme directionality
(Atanasov et al 2004;Banhegyi et al 2004). Combined mutations in H6PDH and
11HSD1 have recently been observed in apparent cortisone reductase deficiency
(Draper et al 2002), a rare and hitherto poorly understood condition in which
impaired regeneration of Cortisol from cortisone and compensatory activation of the
HPA axis results in ACTH-dependent adrenal androgen excess (Phillipou et al
1996;Jamieson et al 1999), although other studies suggest these mutations may exist
in unaffected individuals (White 2005). Cofactor availability may be an important
mechanism mediating acute changes in 11HSD1 activity. Potential regulators of
H6PDH remain unknown but as glucose-6-phosphate is the primary substrate for
H6PDH, nutritional state and cell glucose flux may be important.
1.10 Adipose 11HSD1: downstream effects
At a cellular level, glucocorticoids are known to be involved in differentiation
and proliferation pathways, giving them a speculative role in tumourogenesis and
embryological development (Rabbitt et al 2003). In vitro, glucocorticoids are
required for the differentiation of stromal cells to mature adipocytes (Hauner et al
1987), and in vivo, 11HSD1 activation may regulate this process. Stromal cells
contain 11HSD1 activity which is higher in omental than subcutaneous adipocytes
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(Bujalska et al 1999). Commitment to adipogenesis is associated with a switch in
11HSD1 enzyme activity from dehydrogenase to oxoreductase (Bujalska et al
2002b), a process potentially mediated by cofactor availability through H6PDH.
Activation of adipose 11HSD1 in obesity may therefore result in increased
adipogenesis, thus perpetuating underlying obesity.
Complications of obesity include hypertension, dyslipidaemia and insulin
resistance. A number of key genes controlling these metabolic processes are
glucocorticoid regulated e.g. angiotensinogen, hormone sensitive lipases, aromatase,
glucose transporter 4 and leptin. Increased intraadipose Cortisol generation (by
11HSD1) and GR activation may therefore be important in mediating downstream
metabolic effects in human obesity. The metabolic impact of altered adipose
11HSD1 is however best assessed by enzyme inhibition.
1.11 11HSD1 Inhibition
Various compounds have been shown to inhibit llHSDs, but none until
recently were selective, potent and drug-like. Liquorice based compounds such as
glycyrrhetinic acid or carbenoxolone (previously used as an anti-ulcer treatment)
inhibit 1 lHSDs but select poorly between the different isoforms (type 1 and type 2)
(Monder et al 1989). Side effects as a result of 11HSD2 inhibition include
hypertension, fluid retention and hypokalaemia. Many other non-specific inhibitors
exist including alcohol, bioflavinoids, triterpenoids, polyphenols in cotton seed,
grapefruit juice and tea, and environmental agents such as gossypol (Zhang & Wang
1997;Hult et al 1998). In view of the potential wide ranging benefits of type 1
enzyme inhibition, the search for more selective inhibitors of 11HSD1 has been
hastening. Chenodeoxycholic acid is a selective inhibitor of the 11HSD type 1 but
drug potency is poor (Diederich et al 2000). A new class of both potent and selective
inhibitors of 11HSD type 1 is emerging called the arylsulfonamidothiazoles (Barf et
al 2002). Also, insulin sensitizing thiazolidinediones (PPAR-y agonists) may mediate
their action in part through inhibition of adipose 11HSD1, an effect demonstrated in
cultured adipocytes (Berger et al 2001). Likewise, the lipid lowering agent
fenofibrate (a PPAR a agonist), inhibits 11HSD1 in hepatocytes (Hermanowski-
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Vosatka et al 2000). A number of these compounds have been employed in in vitro
and in vivo studies. The key target tissues examined so far are liver and adipose.
1.11.1 In vitro studies
11HSD1 inhibition in vitro can limit regeneration or synthesis of
glucocorticoids and attenuate the biological activity of cortisone on adipose tissue e.g
by limiting adipocyte differentiation (Bujalska et al 1999) and aromatase expression
(Yang et al 1997).
1.11.2 In vivo studies
Treatment of lean and obese Zucker rats with carbenoxolone results in
inhibition of 11HSD1 in the liver but not adipose tissue or skeletal muscle
(Livingstone & Walker 2003). It had no effect on weight gain, food intake, or oral
glucose tolerance but did result in changes in lipid profile (increased HDL
cholesterol). The lack of effect on obesity and insulin sensitivity was attributed to
the lack of adipose inhibition. Similar results have been obtained in humans. In
healthy human volunteers carbenoxolone improve insulin sensitivity (Walker et al
1995) without a measurable increase in forearm glucose uptake (principally skeletal
muscle) and so was attributed to enhanced hepatic insulin sensitivity. Reduced
hepatic 11HSD1 activity may result in impaired hepatic gluconeogenesis as a result
of modulation of key glucocorticoid responsive gluconeogenic enzymes (e.g.
PEPCK). A further study in lean diet controlled type 2 diabetic patients and control
healthy volunteers demonstrated reduced glucagon stimulated hepatic glucose
production and glycogenolysis in diabetics and reduced total cholesterol in healthy
volunteers upon carbenoxolone treatment (Andrews et al 2003), but no increase in
glucose uptake. Further Sandeep et al recently showed no improvement in insulin
sensitivity in obesity with carbenoxolone attributable to a lack of effect in adipose
tissue (Sandeep et al 2005).
Arylsulfonamidothiazoles (Barf et al 2002) show encouraging results in
animal studies, with lowering of blood glucose in diabetic mice. These effects seem
to be mediated through inhibition of glucocorticoid-dependent expression of PEPCK
and glucose-6-phosphate as a result of 11HSD1 inhibition in the liver (Alberts et al
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2002;Alberts et al 2003). Hermanowski-Votsaka et al has since shown that selective
11HSD1 inhbition lowered body weight, insulin, fasting glucose, triglycerides, and
cholesterol in diet-induced obese mice and lowered fasting glucose, insulin,
glucagon, triglycerides, and free fatty acids, as well as improved glucose tolerance,
in a mouse model of type 2 diabetes. In addition, inhibition of 11HSD1 slowed
plaque progression in a murine model of atherosclerosis (ApoE knock out
mice)(Hermanowski-Vosatka et al 2005).
What remains to be established for any human 11HSD1 inhibitors is whether
their effects extend beyond the liver and include benefits in adipose tissue. This is
especially important in obesity, where liver 11HSD1 levels are already low but
adipose 11HSD1 is pathologically elevated. It is intuitive that inhibition of adipose
11HSD1 is therefore likely to give the most therapeutic benefit while any additional
inhibition in liver may have limited value. The development of drugs with
amphipathic or hydrophobic properties that facilitate sequestration in adipocytes may
therefore be particularly useful.
1.11.3 Caveats regarding 11HSD1 inhibitors
11HSD1 is found in many other tissues (e.g. gonads, lung, immune cells,
vascular tissues and bone) (Seckl & Walker 2001). Side effects of global inhibition
could therefore be wide ranging. Reassuringly, 11HSD1-/- mice are healthy and live
a full life span and reproduce normally (Morton et al 2001). Further they maintain an
advantageous metabolic phenotype throughout life suggesting that compensatory
mechanisms do not over-ride the effects of 11HSD1 loss. A more likely side effect of
11HSD1 inhibition is that of increased adrenal androgen production. This is seen in
individuals with apparent cortisone reductase deficiency as a result of reduced
peripheral Cortisol production, leading to secondary activation of the HPA axis and
subsequent activation of adrenal androgen pathways (Phillipov 1998). 11HSD1
inhibition may also affect the response to inflammation and infection.
Glucocorticoids are widely known for their anti-inflammatory action, and circulating
cytokines (e.g. TNF-a and IL-1) can increased tissue glucocorticoids (via HSD1)
(Tomlinson et al 2001) thus limiting the inflammatory response. Further, 11HSD1
may be required for the differentiation of monocytes to macrophages (Thieringer et
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al 2001). Altered response to inflammation and infection may therefore be a potential
side effect of 11HSD1 inhibition. Ultimately, uncertainties of side effects of therapy
can only be answered in trials of 11HSD1 inhibitors.
1. 12 11HSD1; Conclusions
The role of 11HSD1 as a potential therapeutic target in obesity and the
associated 'metabolic syndrome' is attractive. Obesity is now reaching epidemic
proportions in the western world and health resource implications are enormous.
Lifestyle advice rarely results in long term weight reduction, and pharmacological
targeting of pathways involved in metabolic consequences (i.e. insulin resistance,
dyslipidaemia and hypertension) may be the best option to prevent the otherwise
inevitable increased burden of cardiovascular disease. It seems unlikely that the
majority of idiopathic obesity is due to an underlying protein or coding defect in
11HSD1, but rather that altered 11HSD1 expression is a result of abnormal gene
regulation as a consequence of other metabolic disturbances in obesity. This does not
however preclude the usefulness of 11HSD1 as a therapeutic target. Indeed, its
physiological importance and tissue specific dysregulation in many common diseases
make it a potentially important and novel therapeutic target. With the development of
specific inhibitors, the real potential of 11HSD1 inhibition in the metabolic
syndrome will soon be discovered.
1.13 Sex Steroids and Obesity
In addition to glucocorticoids, sex steroids (androgens and estrogens) play
important roles in determining body fat mass and its distribution, as is evident from
predisposition to 'central' ('abdominal' or 'android') obesity in men and 'peripheral'
('gynoid') obesity in women. In both sexes central adiposity is associated with
adverse metabolic effects and increased cardiovascular risk (Despres et al 1990), and
it has been suggested that it reflects a predominance of androgen action over that of
estrogen (Bjorntorp 1997). However, relationships between circulating sex steroids
and obesity are not simple. In women, central obesity is associated with increased
plasma androgens or free androgen index (Korhonen et al 2003), but in men central
adiposity is associated with reduced testosterone levels (Glass et al 1977;Strain et al
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1982;Zumoff et al 1990) which rise on weight loss (Kaukua et al 2003). Further,
testosterone replacement in mildly deficient men with type 2 diabetes has been
reported to improve central obesity and glucose tolerance (Boyanov et al 2003).
Moreover, circulating estrogen levels are positively associated with body mass index
(BMI) in both post menopausal women (Soler et al 1989), men (Brind et al
1990;Vermeulen et al 2002) and children (Zumoff 1982;Garnett et al 2004).
However, the incidence of obesity is higher among post-menopausal women and
may be ameliorated by hormone replacement therapy (Tchernof et al 2000).
These conflicting findings may reflect the fact that blood levels do not
accurately measure tissue sex steroid action, which as with glucocorticoids, is also
controlled by receptor density and by local steroid metabolising enzymes. Estrogen
receptors (ERcc and ERP)(Pedersen et al 2001;Dieudonne et al 2004), and androgen
receptors (AR) are all present in human adipose tissue, and variations in regional AR
(Joyner et al 2002) expression may explain preferential central fat accumulation.
Obesity occurs in ER-a knockout mice (Couse & Korach 1999;Heine et al 2000) and
in humans is associated with polymorphisms in AR and ER genes (Buemann et al
1997;Zitzmann et al 2003;van Rossum et al 2003;Di Blasio et al 2003;0kura et al
2003;van Rossum & Lamberts 2004). However, whether variations in sex steroid
receptor expression in adipose tissue are important in determining variations in body
fat and its distribution across the population is unknown.
Steroid metabolising enzymes control tissue sex steroid concentrations and
hence ligand availability for intracellular receptors (summarised in Fig 1.5),
(Belanger et al 2002), but their role in idiopathic human obesity remains largely
unexplored. Intra-adipose aromatase modulates the conversion of androgens to
estrogens (androstenedione to estrone, and testosterone to estradiol). Humans with a
rare loss of function mutation in the aromatase gene (resulting in predominance of
androgens over estrogens) have a metabolic syndrome, abdominal obesity and insulin
resistance (Simpson 2000a). Aromatase knockout mice also have marked abdominal
adiposity, hepatic steatosis, dyslipidaemia, hyperleptinaemia and hyperinsulinaemia
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Schematic of Tissue Sex Steroid Metabolism
Summary of tissue estrogen and androgen steroid metabolism and receptor
activation. Aldoketoreductase enzymes have varying degrees of 3a, 170
and 20a-HSD activity as discussed in sections 1.13 and chapter 6.
3aHSD = 3-alpha hydroxysteroid dehydrogenase, 5aDHT= 5 alpha dihdro-
testosterone, 170-HSDs= 17beta hydroxysteroid dehydrogenase, ER=
estrogen receptor, AR= androgen receptor
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to 5a-reduced metabolites (5a-dihydro-testosterone) which have increased potency
at AR. 5a-Reductase activity is present in adipose (Killinger et al 1990) but the
isozyme responsible and its role as a moderator of adiposity is unknown.
New interest is also emerging in the aldoketoreductase family of enzymes
which have varying degrees of 3a, 20a and 17p-reductase activity and may therefore
be key determinants of glucocorticoid, progesterone, estrogen and androgen
metabolism (Penning et al 2000). One isoform, AKR1C type 1, has been studied in
human sub-cutaneous and omental adipose tissue and its activity in omental adipose
related to degree of central obesity (Blanchette et al 2005). The role of other AKRs
in adipose tissue is unknown, but the main effects may be to regulate androgen
activation or inactivation in addition to acting in concert with 5a-reductase in the
inactivation of dihydro metabolites of pregnene steroids, including androgen,
glucocorticoids and progestogens. Although this thesis concentrates on the role of
glucococorticoids metabolism in obesity, the final chapter will assess aspects of sex
steroid metabolism also.
1.13 Hypothesis and Aims
Whilst evidence for a role of altered glucocorticoid metabolism in obesity is
strong, the factors mediating this and the impact on the metabolic phenotype is
unclear. Further, many studies detailing regulation and downstream consequences
have been performed either in animal models or in vitro in cell culture and the impact
in idiopathic human obesity is uncertain. Against this background, I aimed to assess
whether adipose 11HSD1 is transcriptionally upregulated in human obesity, to
determine potential key regulators and to assess impact on downstream gene
transcription and metabolic outcomes. In light of the evidence for the importance of
tissue glucocorticoid metabolism in obesity, I finally explored whether a similar role
exists for key enzymes metabolising sex steroids in adipose tissue. To address this
broad agenda, I undertook studies with the following aims:
In chapter three, I analysed adipose biopsies from three separate healthy volunteer
cohorts from Sweden, Finland and America to answer the following questions:
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1. Is adipose 11HSD1 activity elevated in obesity and associated with changes
in 11HSD1 mRNA?
2. Does adipose 11HSD1 activity predict tissue Cortisol and cortisone levels?
3. Does elevated 11HSD1 activity regulate downstream target genes in adipose?
4. Does elevated adipose 11HSD1 activity predict downstream metabolic
phenotypes e.g. degree of insulin sensitivity, hypertension and dyslipidaemia?
In chapter four, I described studies performed in vivo in healthy volunteers and in
vitro in primary adipocytes to assess regulation of Cortisol metabolism by insulin and
lipid to determine:
1. Is adipose 11HSD1 acutely regulated in vivo by acute hyperinsulinaemia or
hyperlipidaemia?
2. Is acute regulation of 11HSD1 secondary to changes in enzyme
directionality?
3. Is whole body Cortisol metabolism and clearance (via 5a- and 5P-Reductase)
regulated by nutritional factors?
4. Is regulation of 11HSD1 by insulin/ glucose in vitro secondary to
transcriptional or post-transcriptional changes and mediated primarily by glucose
flux or insulin signalling?
In chapter five, I described studies performed in vivo in healthy volunteers to assess
regulation of Cortisol metabolism by PPAR agonists to determine:
1. Is adipose, liver and 'whole body' 11HSD1 regulated in vivo by PPAR-y and
PPAR-a agonists?
2. Is Cortisol clearance regulated by PPAR agonists?
In chapter six, I explored the role of sex steroid as mediators of adiposity. Using
adipose biopsies from previously described healthy volunteer cohorts (chapter 3), I
assess mRNA expression of enzymes and receptors dictating sex steroid action in
adipose to determine:
1. Do enzymes and receptors mediating oestrogen and testosterone action in
adipose predict metabolic phenotypes, as suggested by genetic models?
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2. Are there significant relationships between steroid metabolising enzymes/
receptors and potential regulators and downstream targets?
Finally, in chapter seven, I will draw conclusions from the above studies on the






Unless otherwise stated, chemicals and reagents were purchased from Sigma, Poole,
UK.
All HPLC grade solvents were from Rathburn Chemicals, Walkerburn, UK.
All epi-steroid standards were from Steraloids, Newport, USA.
All radioactivity was from Amersham, Bucks, UK.
Deuterated Cortisol tracer (d4F) was obtained from Cambridge Isotope Laboratories
(Cambridge, MA).
Lipidex 5000 was obtained from Canberra Packard (Pangourne, UK).
Sep Pak Ci8 cartridges were obtained from Waters Corp (Glasgow, UK).
Sources other than these are indicated in parentheses.
2.2 Commonly used Buffers and Solutions
Acetate buffer. 0.2M sodium acetate, pH 4.6. Stored at 4°C.
DEPC-treated water: Distilled water (500ml) mixed with diethylpyrocarbonate
(DEPC; 5 drops) and left for l-24hrs before autoclaving.
Loading buffer. 0.25% bromophenol blue, 0.25% xylene cynol, 25% Ficoll made up
in DEPC-treated water.
IOx MOPS 0.2M 3-[N-morpholino] propanesulforonic acid, 50mM Na acetate, 5mM
EDTA, pH7. Autoclaved before use.
Phosphate Buffer: 0.2M NaH2P04, 0.6M Na2HP04, 5mM ethylenediaminetetraacetic
acid. Autoclaved before use.
lOx TBE buffer: 56g Tris, 57.5g boric acid, 20ml 0.5M EDTA, made up to 500ml
with distilled water. Autoclaved before use.
Kreb's (KRB)Buffer: 118mM NaCl, 3.8mM KCL, 1.19mM KH2P04, 2.54mM CaCl2,
1.19mM MgS04j 25mM NaHC03 (bubbled with oxygen for 1 hr), pH 7.4. Stored at
4°C and supplemented with 0.2% glucose immediately prior to use.
KRH buffer: 118mM NaCl, 5mM NaHCOs, 4.7mM KC1, 1.2mM KH2P04, 1.2mM
MgSO4..7H20, 25mM HEPES, 2.5mM CaCl2
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2.3 Introduction to Methods
All clinical measurements, sample collection and analyses (using the assays
described in this chapter) were carried out personally by the author, after appropriate
technical advice and training and with the assistance of Wellcome Trust Clinical
Research Facility nursing staff. The only exceptions to this were; clinical
measurements in Swedish, Finnish and American cohorts (chapter 3 and 6) (carried
out in the centre of origin) and measurement of plasma biochemistry (section 2.6.1.)
which was carried out in the clinical biochemistry laboratories (Western General
Hospital, Edinburgh).
Most methods described were already in routine use within our research
group. I therefore learned techniques from experienced individuals and adapted these
for use in my studies. Some methods however had to be developed de novo and
required considerable personal methodological development. These included i)
needle adipose biopsy (2.4.2) ii) intra-adipose analysis of steroid measurements
(2.7.3) iii) and mRNA analysis of human adipose. This included personally
designing all real time primers and development of a real-time PCR assay for human
adipose (2.7.2).
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2.4 Clinical Procedures for Human Studies
2.4.1 Recruitment
2.4.1.1 Adipose Biopsy Analysis ofoverseas cohorts (chapters 3 and 6)
Recruitment, measurement of clinical parameters, and method of adipose biopsy is
described in chapter 3, separately for each cohort.
2.4.1.2 In vivo regulation studies (chapters 4 and 5)
Male healthy volunteers between the ages of 20 and 70 were recruited
locally, by newspaper advertisement, for in-vivo regulation studies. General criteria
for inclusion were: normal thyroid, renal and hepatic function, alcohol intake
<28units per week, and no glucocorticoid use in the previous 6 months. Each study
had its own BMI criteria (see individual chapters). Local ethical approval (Lothian
regional ethics committee) and written consent were obtained for each study. Clinical
studies were carried out in the Wellcome trust clinical research facility, Western
General Hospital, Edinburgh. If a volunteer 'dropped out' of the study, they were
replaced to maintain numbers. Only individuals who had taken part in all study
phases were included in the final analysis.
2.4.2 Needle Adipose Biopsy
Needle adipose biopsies were taken for investigation of regulation of
Cortisol metabolism. Skin laterally to the umbilicus was cleaned with Betadine (SSL,
Knutsford, UK) and 5ml local anaesthetic (Lignocaine l%,Braun UK) infiltrated
locally. Sub-cutaneous adipose tissue was extracted using a 14G biopsy needle
(Sterican, B. Braun, Melsungen, AG), attached to a sterile 60ml luer lock syringe to
provide vacuum. The tissue was then washed with DEPC treated water prior to
transfer to a sterile ependorf for immediate freezing on dry ice. This was then stored
at -80°C until further use.
2.4.3 Intra-adipose Microdialysis (figure 2.1)
In vivo abdominal sub-cutaneous adipose 11HSD1 activity was assessed
using microdialysis (nutritional regulation studies- chapter 4 and 5). Volunteers













Intra-adipose Microdialysis. In vivo 11HSD1 reductase and
dehydrogenase activities were assessed by intra-adipose microdialysis
(equipment photographed above and diagram below). 3H Cortisol/
cortisone infused separately at a rate of 0.3pl/min. The effluent was
collected every hour and analysed for % conversion.
53
10cm laterally to the umbilicus was cleaned with Betadine (SSL, Knutsford, UK) and
5ml local anaesthetic (Lignocaine 1%, Braun, UK) infiltrated locally. A CMA 60
microdialysis cannula (containing 20kD-permeable membranes) (CMA
microdialysis, Sweden) was inserted into the subcutaneous adipose. 3H -steroids
were diluted in compound sodium lactate sterile solution (300kBq in 2.5ml) prior to
infusion. For 11-ketoreductase (RED) and 11 P-dehydrogenase (DH) activities,
respectively, 3H-cortisone (67 nM) or, in a separate cannula in the opposite side of
the abdomen, 3H-cortisol (50 nM) were infused (at 0.3 pl/min) using a CMA 106
microdialysis pump. The effluent was collected at hourly intervals into microvials
and tracer Cortisol and cortisone were quantified as described in (Sandeep et al
2005) and detailed in section 2.5 below.
2.4.5. Intra-venous (9,11,12,12-2H4) Cortisol Tracers
I was keen to avoid the pitfalls of previous work which relied on urinary
metabolite ratios and ex vivo assays of glucocorticoid turnover as a true measure of
11HSD1 activity. In addition, I wanted to use a technique which would allow
accurate and detailed assessment of very acute changes in enzyme regulation in vivo
in humans. I therefore adapted an intravenous Cortisol tracer technique which had
been developed and validated by Andrew et al (Andrew et al 2002). Infusion of
intravenous (9,11,12,12-2H4) Cortisol (d4F) with subsequent measurement of
generated d3E and d3F in the plasma allowed an in vivo assessment of Cortisol
turnover by llHSDs (figure 2.2). The rate of appearance of d3F and tracer;tracee
ratio give a measurement of whole body 11HSD1 activity. In addition, analysis of
tracer glucocorticoid metabolites in the urine allows assessment of A-ring reductase
activity.
Subjects attended between 0800 and 0900 after an overnight fast. Subjects
were given Cortisol/ (9,11,12,12-2H4) Cortisol (d4F) [20 atoms percent (AP)] as a
bolus injection (3.6mg total), followed by a constant infusion (20AP, 17.4mg/hr).
Blood samples were withdrawn from the opposing arm at frequent intervals. Subjects
provided a urine sample at baseline and then at intervals throughout the study (see










Stable Isotope Tracers for 11-HSDs in man
Schematic of metabolism of (9,11,12,12-2H4) Cortisol tracer by llHSDs
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Blood samples were maintained on ice, centrifuged and serum extracted. Plasma and
urine were stored at -20 °C pending analysis (see section 2.8).
2.4.6 In vivo Liver 11HSD1 activity (conversion of oral cortisone to plasma Cortisol)
In vivo liver 11HSD1 activity was assessed by measuring conversion of
cortisone to Cortisol on first pass through the liver after overnight dexamethasone
suppression. Volunteers attended fasted at 0900 having taken dexamethasone lmg
(Merck, Sharpe and Dohme Ltd, Herts, UK) at 2300 the evening before, and a
venous cannula was inserted to allow repeated blood sampling. Oral cortisone acetate
(25mg) (Pantheon UK Ltd, Swindon, UK) was given with water. Plasma samples
were collected in lithium heparin tubes (2.6ml), centrifuged at 2380rpm for 10 mins
at 4 °C and plasma aliquoted and frozen until analysis for serum Cortisol. Samples
were taken at time points: 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150,
165, 180, 210 and 240 minutes after oral cortisone.
2.5 Microdialysis Analysis; Steroid Extraction and TLC
The volume of effluent from microdialysis microvials was assessed and
made up to 250pl with Ringers Buffer. Ten times volume of ethyl acetate was added
and the samples mixed and centrifuged at 1500rpm for 5 mins. The supernatant was
removed and dried under oxygen free nitrogen (OFN) at 60 °C. Samples were diluted
in 30pl of 1.67mg/ml solution of cold Cortisol and cortisone and transferred to TLC
plates (DC-Alufolien, Merck, Darmstadt, Germany). Cortisol and cortisone were
separated by thin layer chromatography (TLC) over 1 hr using a solvent mix (92mls
chloroform and 8mls 95% ethanol) . Cortisol and cortisone bands were identified and
marked by viewing under UV. Individual bands were scraped into scintillation vials
3 3and H-cortisone and H-cortisol quantified by addition of 5mls scintillation fluid
(Perkin Elmer, Boston, MA) and counting for 30mins in the scintillation (p) counter
(Tri-Carb 2100TR, Liquid Scintillation Analyser, Packard, UK). Reductase and




125Plasma Cortisol was assessed using ImmunChem Cortisol I RIA coated
tube kit. This containing pre-prepared standards (Omg/dl to lOOug/dl), tubes with
impregnated Cortisol antibody and Cortisol 125I (lml=approx 45,000cpm). 25ul of
standard, control or plasma sample was pipetted into coated tubes. 1ml of Cortisol 125I
was added to all tubes and vortexed. Samples were incubated for 45 mins at 37 °C.
Tubes were placed in gripping racks, decanted and counted in a gamma counter
calibrated for 125I (Berthold LB2111, Leeds, UK). A standard curve was produced
and sample values derived from the standard curve.
2.6.1. Plasma Insulin, Trigs, Glucose, Cholesterol, HDL, LDL, FFA, C-Peptide, U
and Es
Enzyme immunoassays (Eurogenetics Tasah Corp. UK Ltd., Hampton, UK)
were used to measure plasma insulin and C peptide. Electrolytes were measured with
a Vitras 950 (Ortho Diagnostics, Raritan, NJ), and glucose was determined on a
Cabas Mira Plus (Roche, Mannheim, Germany). Triglycerides, total cholesterol, and
high density lipoprotein (HDL) cholesterol was measured using ELISA kits (TG,
CHOL, and HDLC-plus respectively, Roche). Free fatty acids were measured by a
colorimetric technique (Wako, Neuss, Germany).
2.7 Adipose Biopsy Analysis
2.7.1 In vitro 11HSD1 activity assay
2.7.1.1 Tissue preparation
Tissue was routinely frozen on dry ice directly after the adipose biopsy and
stored at -80°C until use. Approx 250-500mg of adipose tissue was homogenised in
3ml of KREBs buffer. Homgenates were centrifuged at 300G at 4 °C for 5 min and
the infranatant removed.
2.7.7.2 Protein estimation
Protein concentration of tissue homogenates was determined
colorimetrically using a Bio-Rad protein assay kit (Bio-Rad, Hemel Hampstead,
UK). A range of protein standards (0.1 - 1.2mg/ml) was prepared in distilled water
from the provided protein standard. Protein assay dye reagent was prepared by
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diluting the concentrate provided by 1 in 5 with distilled water. Diluted protein assay
dye reagent (1.96ml) was added to 40ul of either protein standard or appropriately
diluted sample in a borosilicate tube, vortexed and left at room temperature for 15 -
30 mins. The absorbance of the samples at X =595nm was measured using a
OPTIMAX tunable microplate reader and the concentration of protein in each sample
was estimated from the standard curve.
2.7.1.3 In vitro 11HSD1 activity assay
In vivo, 11HSD1 functions as a predominant reductase (converting inactive
cortisone to active Cortisol). In vitro however, reductase activity is labile and
dehydrogenase activity predominates in tissue homogenates. 11HSD1 activity was
therefore quantified by the conversion of Cortisol to cortisone. Aliquots of adipose
homogenate at a concentration of 400ug/ml were incubated in duplicate at 37 °C in
Krebs buffer containing 0.25% glucose, NADP (2mM) and [3H]-cortisol (F)
• *3
(100nM) in a total volume of 1ml. Blanks were prepared by incubating [ H]-cortisol,
NADP and buffer with no tissue added. After the incubation the reaction was
stopped by the addition of 10 volumes of ethyl acetate (all solvents used were HPLC
grade). The organic phase was removed and evaporated under oxygen free nitrogen
at 60 °C. Extracts were re-suspended in mobile phase (65% methanol, 10%
acetonitrile and 25% water) and stored at -20 °C until analysis by high pressure liquid
chromatography.
This in vitro assay for 11HSD1 activity has been used widely in the published
literature. In vitro, dehydrogenase activity is a more stable measurement than
reductase and reflects protein levels well. We appreciate that no amount of
measurement of in vitro enzyme activity in either direction can allow a true
interpretation of the in vivo directionality. This issue can only be addressed by in situ
measurements as illustrated by the in vivo microdialysis studies in chapters 4 and 5.
2.7.1.4 High Pressure Liquid Chromatography (figure 2.3)
A lOOp.1 aliquot of each sample in mobile phase (65% methanol, 10%
acetonitrile and 25% water) was injected into the high-pressure liquid




HPLC Trace for in vitro Adipose 11HSD1 activity assay
11HSD1 reductase activity was assessed in whole adipose biopsy
homogenates after 3,6,20 and 30hr incubations. E (cortisone) and F (Cortisol)
were separated by HPLC (see figure). % conversion was calculated from
area under curve of E and F peaks.
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auto-injector, mobile-phase pump, reverse phase p-Bondapak cl8 column in a
column heater and a Berthold (Leeds, UK) radioactivity monitor linked to a
scintillation fluid pump. The system is controlled by a computer with Winflow
software (JMBS Developments, France). The flow of mobile phase was set at
0.7ml/min and the flow rate of scintillant was set at 2.0ml/min. to achieve optimal
mixing and efficiency of counting. The column heater was set at 35 °C to improve
chromatography and maintain stability of retention times. Radioactive standards
were injected at the start of every run to confirm the identity of the peaks. The
retention time for cortisone (E) was approximately 32 mins, and for Cortisol (F)
approximately 36 mins. The area under the peak was integrated using the Winflow
software, and the proportion of the area of each peak used to quantify the conversion
of [3H]-cortisol (F) to [3H]-cortisone (E) and hence 11HSD1 activity. Routine blank
incubations with no tissue were performed for each assay and the conversion in each
sample was corrected for the apparent conversion in the blank.
2.7.2 mRNA quantification
2.7.2.1 RNA extraction
Tissue was routinely frozen on dry ice directly after the adipose biopsy and
stored at -80°C until use. Approximately 250-500 mg of fat was homogenised in 1.5
ml Trizol (registered trademark of Gibco, UK). Samples were centrifuged at 12,000g
for 1 min and the infranatant removed. Chloroform was added (250ml per 1ml of
Trizol), samples vortexed and left on ice for 15mins. Samples were spun at
12,000rpm at 4°C for 15mins, and the upper layer removed and transferred to a new
sterile eppendorf. RNA was purified using by addition of 20pl of RNAid RNA
binding matrix (Anachem, Luton, UK). Samples were washed 3 times in wash buffer
matrix (Anachem, Luton, UK), and dissociated by addition of a solution of
89%DEPC H20/ 10%DTT (lOmM) /l%RNAsin (approx 201). RNA was quantified
using spectrophotometric analysis at OD26o- RNA was stored at -80°C until further
use.
RNA integrity was checked by electropheresis on a 1.2% agarose/ TBE gel
containing ethidium bromide lpl per 50ml gel (figure 2.4a). The gel was made with
ultra-pure water and gel tank equipment sterilized by soaking in sodium hydroxide.
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Figure 2.4
RNA/ PCR Gel photographs, a) Shows Adipose Biopsy RNA (lug) from
multiple samples run out on a 1.2% agarose/ TBE gel. b) Shows 11HSD1
mRNA amplification by PCR from human adipose, not present in control
samples, c) Shows PCR amplification of adipose biopsy mRNA for GR-a,
GR-P, 11HSD1 and Angiotensinogen to check cDNA synthesis and test
specificity of primers designed for subsequent real time PCR. NTC= No
template control
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1 jag of RNA with 2jli1 loading buffer was run at 100V fro l-1.5hrs. The gel was
viewed at 254 (uv) for the presence of clear ribosomal bands and lack of degradation.
2.7.2.2 cDNA synthesis
Oligo dT-primed cDNA was synthesized from 0.5 pg of RNA samples
using Promega Reverse Transcription System (Promega, Southampton,UK). 0.5pg
RNA was incubated with 5mM MgCl2, lx RT buffer (lOmM Tris-HCL, 50mM KC1,
1% Triton X), ImM dNTPs, lu/pl RNase inhibitor, AMV RT (15u/pl) and Oligo(dT)
15 primers (0.5pg) in a total volume of 20pl (made up with NF-water) at 42 °C for
lhr, then 99 °C for 5 mins. For each batch of cDNA synthesis, additional samples
(50% chosen at random) (0.5pg) were also incubated in the absence of reverse
transcriptase (volume replaced with NF-water). These samples (called RT-) were
used as controls in PCR and real time PCR to ensure that genomic DNA
contamination (rather than cDNA) is not being amplified.
2.7.2.3 PCR
cDNA was diluted 1 in 4 with nuclease free water and cDNA synthesis
checked by PCR using primers for either 11HSD1 or p2-microglobulin.
llpHSD type 1 primers (440bp product): 5'AAAGTGATTGTCACWGGGAG
CAAA-3' (forward) 5'-ATCCARAGCAAACTTGCTTGC-3'
p2-microglobulin primer 5' - TGT CTT TCA GCA AGG ACT GGT C - 3' (forward)
and 5'- TGA TGC TGC TTA CAT GTC TCG AT - 3' (reverse).
PCR was carried out using 5pl of cDNA template, lx Taqman bead in lx PCR
buffer, MgCl2 (1.5mM), dNTPs (200pM), forward primer (40pmol), reverse primer
(40pmol) in a total volume of 50p.l (made up with NF-water). (All PCR reagents
Promega, Southampton, UK). lOp.1 of PCR products were mixed with 2pl loading
buffer and run on a 1.75% agarose/ TBE gel with 1Kb DNA ladder (figure 2.4b).
PCR was also performed using specific primers (below) for the 4 human
isoforms of AKR1C (chapter 6). PCR was performed at 20, 30 and 40 cycles
(denaturing at 94 degrees for 2 mins, then for each cycle 45sec denaturing step at 94
degrees, a 45 sec annealing step at 60 degrees and a 2 minute extension step at 72
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degrees) to assess comparative expression of the 4 isoforms and 500bp products run
on a 1.25% agarose/ TBE gel (fig 6.2).




AKR1C3 5' -dGTAAAGCTTTGGAGGTCAC-3' (F),
5' -dCACCCATCGTTTGTCTCGT-3' (R),
AKR1C4 5 '-dACAGAGCTGTAGAGGTCAC-3 '(R),
5' -dCACCCATAGTTTATGTCGT-3' (R),
2.7.2.4 Real time PCR (mRNA quantification)
Transcript level quantification was performed with Real Time PCR primer-
probe sets, using the ABI PRISM 7700/ 7900 Sequence Detection System (Applied
Biosystems, Southampton, UK). Primers and probes were designed using Primer
Express Software (Applied Biosystems, Southampton,UK) to meet the following
specifications: Primer: Tm 58-60 °C, 20-80% GC, length 9-40 bases, <2°C difference
between primers, maximum of 2 G/C's in the last 5 bases at 3' end . Probe: Tm 10 °C
higher than primer Tm, 20-80% GC, length 9-40 bases, no G on the 5' end, <4
contiguous G's, must have more C's than G's. Gene sequences were obtained from
PubMed fhttp://www.ncbi.nlm.nih.gov/entrez/querv.fcgi) or Ensembl Genome
Browser (http://www.ensembl.org/). All primer/ probe sets were designed with at
least one primer or probe spanning an intron, to prevent amplification of genomic
DNA.
























5 'TAACCACATAACATTTTCATGCAT AGAA T3'(R),
5'-6-FAM-TTTGTCAGTTGATAAAACCGCTGCCAGTTCT-TAMRA-3'(probe)
ER-a 5' AAGAGAAGTATTCAAGGACATAACGACTATAT3' (F),
5'CAGCTCTTCCTCCTGTTTTTATCAA3' (R),
5'-6-FAM-TGTCCAGCCACCAACCAGTGCAC-TAMRA 3' (probe)


































cDNA was incubated with lx Taqman mastermix (Applied Biosystems,
Cheshire, UK), 25pM primers and 5pM probe (lpl cDNA per 10 pi, made up to
volume with NF-water) and transferred to 384 well PCR plates with optical heat
sealing cover (Applied Biosystems, Cheshire, UK) . These were centrifuged and
transferred to ABI PRISM 7900 Sequence Detection for cycling/ detection as per
manufacturers instructions. (50°C, 2 min; 95°C, 10 min; 95°C, 15 sec and 60°C, 1














mRNA quantification using real time PCR. Amplification plots showing
cycle number (ct) v's change in fluorescence (delta Rn) for adipose biopsy
mRNAs (Finnish cohort, n=19 men). mRNAs shown are a) Cyclophilin
(dye=VIC), b) 5-alpha reductase type 1 (dye=FAM), c) PPAR-y
(dye=FAM), and d) LPL (dye=FAM).
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Human cyclophilin A primers/probes (20x) (purchased pre-made from
Applied Biosystems, Cheshire, UK) were used to normalize the transcript levels. A
standard curve for each primer probe set was generated in triplicate by serial dilution
of cDNA pooled from several subjects. Each sample was run in duplicate and the
mean values of the duplicates were used to calculate transcript level from the
standard curve. The results are expressed as a ratio to cyclophyllin. RT negative
controls and intron spanning primers were used to examine for genomic DNA and
prevent amplification.
2.7.3 Intra-adipose Cortisol/ cortisone levels
2.7.3.1 Steroid Extraction
Following homogenisation in Trizol, the infranatant from the RNA
extraction protocol was used to extract steroids. Approximately 0.3 pmol/ml (<1%
final tissue concentrations) of l,2,6,7-3H4-cortisone and l,2,6,7-3H4-cortisol
(Amersham, Little Chalfont, UK) were added to the homogenate as internal
standards to correct for steroid extraction efficiency. Samples was centrifuged (300g/
5mins) to remove the lipid layer and extracted on a sep-pak (Waters (CI8 cartridges),
Watford, UK), further purified with hexane (1.5ml per sample), dried down and
reconstituted in 400pi phosphate buffer and re-extracted with ethyl acetate (4ml).
Samples were dried under OFN and stored at -20 °C for further use. Samples were
reconstituted in 200pl ethanol; 15pl was removed for F ELISA, and 20pl for E RIA.
These aliquots were dried down and reconstituted in 60pl charcoal stripped serum (F
ELISA) and charcoal stripped serum/ buffer (Cortisone RIA)(see below). Cortisone
and Cortisol analysis using these methods produced similar results to RIAs following
HPLC separation of cortisone and Cortisol. Extraction efficiency for each sample was
assessed by recovery of the 3H-steroid. Steroid concentrations are expressed per g of
wet weight of adipose tissue after adjustment for extraction efficiency. Steroid




Intra-adipose Cortisol was assessed using a salivary Cortisol enzyme
immunoassay kit (Salimetrics LLC, State College PA). This contained an antibody
coated plate, Cortisol standards (0-l.Bpg/dl), wash buffer (lOx phosphate buffer
containing detergents and a non-mercury preservative), diluted 1:10 with deionised
water, assay dilutent (phosphate buffered solution containing a pH indicator and a
non-mercurial preservative), an enzyme conjugate solution of Cortisol labelled with
horseradish peroxidase, a ready to use solution of Tetramethylbenzidine (TMB), a
'STOP' solution of sulphuric acid reconstituted in 12.5ml deionised water prior to
use. 25pl of standards and samples was pipetted into appropriate wells. Standards
and samples were assayed in duplicate. 25pl of assay diluent was used as a 'blank'
and non-specific binding was assessed by addition of assay diluent to wells
containing no antibody). A 1:1,600 dilution of the conjugate was made and mixed
(15pl conjugate and 24ml assay dilutent). 200pl of diluted conjugate was added to all
wells using a multi-channel pipette. The plate was mixed on a rotator for 5 mins and
incubated at room temperature for 55mins. The plate was washed 4 times with lx
wash buffer using a mechanical plate washer. 200pl of TMB was added to each well
using a multichannel pipette. The plate was mixed on a plate rotator for 5 mins and
incubated in the dark for a further 25 mins. Finally, 50pl of STOP solution was
added with a multi-channel pipette, and mixed for 3 mins on a plate rotator
(500rpm). The plate was then read on a plate reader at 450nm (OPTIMAX tunable
microplate reader) within 10 mins of adding the STOP solution.
The average optical density (OD) was calculated for each well. The average
OD for the NSB was subtracted from the average OD of the zero, standards and
unknown. The percentage bound for each standard was calculated by dividing the
average OD (B) for the average OD for the zero (BO). A log-linear regression curve
was calculated for the standards and results calculated from this.
This assay had good sensitivity and specificity for Cortisol (minimum
concentration of Cortisol that can be distinguished from 0 is <0.007ug/dl. Cross
reactivity with other endogenous glucocorticoids or sex steroids was low <1%. (19%
cross reactivity with dexamethasone). Further assay details are available at
www.salametrics .com.
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2.7.3.3 Direct Cortisone RIA
Serum cortisone assays were purchased from Immunovation Ltd
1 9 S
(Southampton, UK) containing antiserum and I RIA. Buffer was made fresh prior
to each assay by the addition of BSA (5g/L), sodium azide (lg/L) to Tris-HCl
50mmoI/L at pH=7.5. Standards (0-500nmol/L) of cortisone in assay buffer were
prepared in batches and frozen at -20 °C. Steroids were extracted as above and
samples reconstituted in charcoal stripped serum. 450pl assay buffer was added to
50pl of samples and 400pl assay buffer with 50pl stripped serum added to 50pl of
standards. Steroid were extracted using 5ml chloroform, the upper layer aspirated
and duplicate 1ml aliquots taken into glass tubes and dried down under oxygen free
nitrogen (OFN). To the dried extracts we added 300p.l of Tracer (10nCi/300pl in
assay buffer) and lOOpl of antiserum N137 (in 500 dilution in assay buffer), then
vortexed the samples and left them at room temperature for 2hrs. lOOpl of Sac-Cel
(Donkey anti-rabbit) Ab (Wellcome diagnostics, IDS, Boldon, UK) was added and
the samples incubated for a further 30 mins at room temperature. Finally 1ml water
was added, the samples centrifuged, the supernatant aspirated and the tubes counted
in a gamma counter (Berthold LB2111, Leeds, UK). This assay was had good
specificity for cortisone (cross reactivity with Cortisol, cortisone, engogenous Cortisol
metabolites, all <0.1%.; cross reactivity with prednisolone= 20%).
2.8 Gas Chromatography/ mass spectrometry
2.8.1 Urinary steroid examination (endogenous steroid and tracer analysis)
2.8.1.1Preliminary work
Urine samples were collected from volunteers during Cortisol tracer studies
and as 24 hour collections. The total sample volume was noted and aliquots of 20ml
frozen at -20°C for further analysis. Internal standards (epi-cortisol (epi-F) and epi-
tetrahydrocortisol (epi-THF)) and standard curve ranges for a-THF,
tetrahydrocortisone (THE), a-cortol, p-cortol, a-cortolone, and P-cortolone were
prepared.
2.8.1.2 Extraction ofsteroids from urine
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Internal standard (5pg Epi-F and 30pg Epi-THF) was added to urine (20ml)
and standard curve samples before passing through a Sep-Pak Cis column
[conditioned with methanol (5ml), then water (5ml)]. The column was washed with
5ml water and samples and eluted with 2ml methanol. Samples were dried under
OFN.
2.8.1.3 Hydrolysis ofsteroids
Samples were incubated with 2ml 0.2M Sodium Acetate and lOOpl p-
Glucoronidase, mixed and incubated for 48 hours at 37 °C
2.8.1.4 Extraction ofhydrolysate
Sep-Paks were reconditioned with 5ml methanol and 5ml H20 and samples
passed through, washed with 5ml water and eluted with 2ml methanol. Samples were
dried under OFN. The dried layer was reconstituted in 200pl water and 3ml ethyl
acetate and the organic layer removed and dried under OFN at 60 °C.
2.8.1.5 Derivatisation ofsteroids
50pl of 2% methoxyamine in dry pyridine was added and the samples
evaporated to dryness at 60 °C. 50pl of trimethlsilylimidazole was added and samples
incubated at 100°C for 2hrs.
2.8.1.6. Extraction ofderivatised steroids
The steroids were extacted from the derived mixture on lipidex 5000
columns which were prepared by adding 1ml of Lipidex 5000 (Canberra Packard,
UK) to glass Pasteur pipettes loosely plugged with silanised glass wool. The lipidex
was prepared in mobile phase (cyclohexane:pyridine:hexamethylsisiIazine; 98:1:1)
and the columns were washed with 3ml mobile phase before use. The samples were
passed through the columns with 1ml mobile phase, and a further 1ml mobile phase
was added to ensure that all the steroid was eluted. The samples were dried under
OFN and reconstituted in hexane in preparation for injection on to the GC-MS
system.
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2.8.2 Plasma Steroid extraction (tracer studies)
2.8.2.1 Steroid extraction from plasma
Plasma (1.5ml) containing epi-cortisol (lpg) as an internal standard was
shaken with chloroform (15ml). The upper layer (plasma residue) was removed with
a Pasteur pipette, and the organic layer transferred to clean tube. The organic layer
was evaporated to dryness under OFN at 60 °C in reactivials.
2.8.2.3 Derivatisation ofsteroids
Plasma steroids were derivatised by addition of 50pl 2% methoxyamine in
dry pyridine to each sample. Vials were capped and heated at 60 °C for 30mins then
evaporated to dryness under OFN at 60 °C. 50pl of trimethylsilylimidazole was
added to each sample and incubated for 2hrs at 100 °C. Samples were passed through
freshly prepared Lipidex columns as described above by addition of 1ml, followed
by 2x 500pl mobile phase (cylohexane:hexamethyldisilazane:pyridine (98:1:1)). The
eluant was collected and dried under OFN at 60 °C. Samples were reconstituted in
lOOpl decane and a 30pl aliquot transferred to GC vials for analysis.
2.8.3 Gas chromatography/ mass spectrometry
Analysis was performed using a 'Voyager', consisting of a Finnigan MD
800 Mass Spectrometer, GC 8000 Top Gas Chromatogram (GC/MS) using a DB17-
MS column (15m, 0.25mm id, 0.25pm ft; J&W Scientific, Folsom, CA). The initial
temperature was 50 °C; this was increased to 200 °C by 30 °C /min and then by 8 °C
/min to 250 °C and then by 6 °C / min to 300 °C and maintained for 6 min. Injection,
source and interfact temperatures were 280, 200, 250 °C respectively. Ionization was
performed in electron impact mode at 70eV. The following ions were monitored to
allow analysis of methoximetrimethylsilyl (MO-TMS) derivative of endogenous
steroid and the tracer and its metabolites: Cortisol m/z 605; d4F, m/z 609; d3F m/z
608; cortisone m/z 531; d3 cortisone, m/z 534; 5p and 5aTHF m/z 652; d4-5P and
5aTHF m/z.656; d3-5p and 5aTHF m/z_655; THE,_m/z 578; d3-THE, m/z 581 . Epi-
cortisol (plasma and urine) and epi-tetrahydrocortisol (urine) were used as internal
standards. Peaks of interest were quantified by the ratio of (area under the peak)/
(area under neighbouring internal standard). Ratios were compared against standard
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curves for each steroid included in every assay batch. For tracer studies, the
enrichment of total steroid with tracer was determined as the APE (i.e. the amount of
tracer divided by the sum of the amount of tracer and tracee, expressed as a
percentage), and this value was corrected for any naturally occurring m+3 and m+4
isotopic components (identified in analysis of samples taken before tracer infusion).
2.8.3.1 Gas chromatography/ mass spectrometry result analysis
i) Unlabelled endogenous steroid analysis
Cortisol, cortisone, THF, aTHF, THE, a-cortol, P-cortol, a-cortolone, P-
and cortolone were measured in 24 hour urine collections for a number of studies
(regulation of llpHSD by PPAR agonists/ inflammatory cytokines; chapters 4 and
5). The balance between 11HSD activities in all tissues was assessed as the ratio of
(5P-THF + 5a-THF)/THE. Renal lip-HSD type 2 activity was assessed as urinary
cortisol/cortisone ratio (Palermo et al 1996;Best & Walker 1997). The balance of 5a-
and 5P-reductases was assessed by the ratio 5P-THF/5a-THF (Andrew et al 1998).
Relative 5a- and 5P-reduction of Cortisol was also assessed by Ulick's A-ring
reduction quotients, 5a-THF/cortisol, 5P-THF/cortisol and 5p-THE/cortisone (Ulick
et al 1992).
ii) Tracer sample analysis: in vivo kinetics (figure 2.2)
Cortisol and cortisone, 9,11,12,12-2H4 Cortisol (d4F),9,12,12-2H4 Cortisol
(d3F) and 9,12,12 2H4 cortisone (d3E) were detected in plasma, and their major
metabolites (unlabelled THF and aTHF, d4- and d3THF and aTHF, unlabelled THE
and d3THE) were also measured in urine over the infusion period.
Rates of appearance of endogenous Cortisol were calculated as [(rate of D4-
cortisol infusion)/(D4-cortisol:cortisol ratio)]-(rate of infusion of corti sol )-(rate of
infusion of D4-cortisol). Clearance of Cortisol and of D4-cortisol were calculated as
(infusion rate)/(steady state concentration). Rate of appearance of D3-cortisol was
calculated as (rate of D4-cortisol infusion)/(D4-cortisol:D3-cortisol ratio).
Urine deuterated steroid excretion rates were calculated for each hour as
(concentration of deuterated steroid) x (volume of urine) (Andrew et al 2002).
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2.9 In Vitro Primary Cell Cultures (chapter 4; glucose/ insulin regulation)
2.9.1 Primary adipocyte culture preparation
Fresh epididymal adipose tissue was isolated from male wistar rats (age 8-
11 months). This was transferred into sterile containers containing KRH buffer (with
adenosine (0.2uM) and 1% bovine serum albumin (BSA) (RIA grade, fraction V,
Sigma, UK) added) at 37 °C (approx 4ml KRH per g fat). Collagenase digestion was
performed using 2mg collagenase (Worthington biochemical corporation, Lakewood,
NJ) per 1ml buffer. The tissue was cut into tiny pieces using sterile scissors and the
tissue incubated in a shaking water bath at 37 °C for 30minutes (shaken vigorously
after 15mins). Tissue was filtered through mesh and washed in x3 in buffer
(centrifuged at 800rpm for 8mins between washes). Adipocytes were removed with a
syringe, transferred to a sterile container, and reconstituted in buffer to make an
approximately 30% adipocyte solution. 300p.l adipocyte solution was added to
200pl solution containing appropriate concentrations of glucose/ insulin/ and steroids
(see chapter 4).
2.9.2 In vitro assessment of 11HSD1 dehydrogenase and reductase activities
To assess dehydrogenase and reductase activity in vitro, adipocytes were
incubated in the presence of either corticosterone (B) or 11-dehydrocorticosterone
(A) respectively (mixture of 25nM 'cold' steroid and 2.5nM 3H- steroid). 3H-A was
made for this assay by incubating placental homogenate in KRB buffer in the
presence of 25nM NAD and 50pl 3H-B for 4hr at 37 °C. The purity of 3H-A was
assessed by HPLC and always >99%. At the end of the incubation period, adipocyte
incubations were transferred to sterile Eppendorfs and spun at 13,000rpm for 1 min.
The lower layer (buffer) was transferred to glass tubes, and steroids extracted using
lml ethyl acetate (solvent layer transferred to a new tube and dried under OFN).
Trizol (lml) was added to the remaining adipocytes and frozen on dry ice for RNA
extraction later. A and B were separated by TLC as discussed above (see section 2.4)
using cold A and B standards rather than E and F.
2.9.3 Assessment of glucose uptake
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lml of a 30% adipocyte preparation was incubated for 15mins at 37 °C in
glucose free KRH buffer. lOnM 'cold' 2-deoxy-glucose and 1:400 dilution of stock
3H-2-deoxyglucose (1.59TBq/mmol/ 49.0Ci/mmol) was added and samples
incubated for a further 3 minutes. 3 x 200pl aliquots were taken into 0.5ml eppendorf
tubes and 200pJ corning oil added. Samples were spun for 1 min at 13,000rpm and
the cell pellet transferred to a scintillant vial with lml 1% Triton (Sigma, UK). After
30 mins, 3ml of scintillant (Perkin Elmer, Boston, MA) was added and samples
counted in the P scintillation-counter.
2.9.4 Reagents for assessment of glucose/ insulin
Glucose was diluted in KRH buffer to make final assay concentrations of
5.6mM (termed 'normal' glucose) or 22.4mM (termed 'high' glucose). Human
'Actrapid' Insulin (Novo-Nordisk, Crawley, UK) was stored at 4°C in a stock
concentration of 500nM. This was diluted in buffer to give a final assay
concentration of 5nM.
2.9.5 mRNA quantification
RNA extraction and mRNA quantification was carried out using real time




5'-6-FAM- CTGGGATAATCTTGAGTCAAGCTGCTCCC -TAMRA-3' (probe).





Statistical methodology for each study is discussed in the appropriate sections of
chapters 3-6. Statistical analyses were carried out using STATISTICA software
version 6.1 (Stat Soft Inc, Tulsa, USA).
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Chapter 3
ADIPOSE GLUCOCORTICOID METABOLISM IN OBESITY AND THE
METABOLIC SYNDROME
3.1 Introduction
The potential importance of 11HSD1 in obesity and the metabolic syndrome
is illustrated by experiments in rodents. In obese Zucker rats (Livingstone et al
2000), 11HSD1 activity is increased selectively in adipose tissue and decreased in
the liver. Selective over-expression of 11HSD1 in white adipose tissue under the
AP2 promoter/enhancer results in central obesity, dyslipidaemia, and insulin
resistance (Masuzaki et al 2001). Conversely, homozygous 11HSD1 'knockout' mice
are protected from features of the metabolic syndrome (Kotelevtsev et al 1997).
Whether similar tissue-specific dysregulation of 11HSD1 occurs in human
obesity has been controversial. Conversion of oral cortisone to Cortisol on first pass
metabolism in the liver is consistently impaired in obese individuals (Stewart et al
1999;Rask et al 2001 ;Virkamaki et al 2001;Rask et al 2002;Tiosano et al 2003),
indicating impaired hepatic 11HSD1. More conventional measurements of in vivo
11HSD activities, such as urinary ratios of cortisol/cortisone metabolites, have been
unhelpful in resolving this controversy (Andrew et al 1998;Stewart et al 1999;Fraser
et al 1999;Reynolds et al 2001;Rask et al 2001;Rask et al 2002;Seppala-Lindroos et
al 2002). There is further uncertainty concerning the impact of altered adipose
11HSD1 on downstream target genes and its role as a mediator of increased adiposity
and the associated metabolic complications in humans. Intra-adipose metabolism of
glucocorticoids may also be dependent on H6PDH (which provides cofactor for
11HSD1), and 5a- reductase which in addition to its role as an activator of
androgens, metabolises glucocorticoids. 5a-Reduced steroids were traditionally
considered inactive excretion products, but have now been shown to have activity at
the Glucocorticoid Receptor (Mclnnes et al 2004).
In this chapter, we report investigations using subcutaneous adipose biopsies
from three different cohorts from a) America (12 Caucasian (7 male, 5 female) and
19 Pima Indian (10 male, 9 female)), b) Finland (n=19 male) and c) Sweden (n=27,
14 male, 13 female) (Rask et al 2001;Rask et al 2002). Adipose biopsies were
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analysed for 11HSD1 activity, 11HSD1, GR, H6PDH and 5a-reductase type
lmRNA, intra-adipose Cortisol/ cortisone levels and glucocorticoid-dependent gene
transcripts. Any difference in procedures from those described in chapter 2 is
highlighted here.
The initial study on Pima Indian and Caucasian male volunteers addressed
whether 11HSD1 is transcriptionally upregulated and altered by ethnicity. The
Finnish study generated detailed measurements of adiposity by MRI and allowed a
clearer assessment of the associations of 11HSD1 with body fat distribution. Finally,
the Swedish study extended these observations into women and addressed the impact
on downstream targets. Each of these studies is individually detailed below.
3.2 Subcutaneous Adipose lip- Hydroxysteroid Dehydrogenase Type 1 Activity
and mRNA levels; Association with Adiposity and Insulinaemia in Pima Indians
and Caucasians
3.2.1 Introduction
In this study, I examined 11HSD1 activity, mRNA levels of 11HSD1 and GR
and tissue Cortisol and cortisone levels in subcutaneous adipose tissue biopsies from
12 Caucasian (7 male, 5 female) and 19 Pima Indian (10 male, 9 female) non-
diabetic subjects aged 28 ± 7.6 years (mean ±SD, range 18-45). We investigated the
cross sectional relationship of human adipose biopsy measurements to metabolic
variables. We examined the hypotheses that i) 11HSD1 activity, mRNA levels and
tissue Cortisol levels are positively related to indices of adiposity, and ii) 11HSD1
activity, mRNA and tissue Cortisol levels are positively related to indices of insulin
resistance and hyperglycemia. We further assessed whether there are ethnic
differences in 11HSD1 activity by examining these relationships in both Pima





Pima and Caucasian volunteers were admitted to the metabolic ward of the
Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health (Phoenix, AZ). Subjects were
recruited by newspaper advertisement or by community based recruiters. While
subjects are not formally matched for adiposity, an effort was made to recruit
Caucasian subjects across a similar range of adiposity as in the Pima group. All
subjects were determined to be in good health by medical history, physical
examination and laboratory screening tests. None was taking medication. Exclusion
criteria included smoking, alcohol or drug abuse, and diabetes, according to a 75g
oral glucose tolerance test (Paterson et al 2004). Upon admission subjects were
placed on a weight maintenance diet (50% carbohydrate, 30% fat, 20% protein)
calculated on the basis of body weight and adjusted to maintain body weight within ±
1%. Body composition, including % body fat (%fat) was assessed by dual energy x-
ray absorptiometry (DPX-1: Lunar, Madison, WI)(Tataranni & Ravussin 1995). The
circumference of the waist was measured supine at the level of the umbilicus. Fat
biopsies were obtained after a 12 hour overnight fast, between 0830h and lOOOh.
Procedures for biopsy have been described previously (Rosmond et al 1998). In
brief, subcutaneous abdominal adipose tissue was removed from the periumbilical
region by percutaneous needle biopsy under local anaesthesia (lidocaine 1%).
Biopsies were frozen immediately at -70°C.
The study was approved by the ethics committee of the National Institute of
Diabetes and Digestive and Kidney Diseases and by the Tribal Council of the Gila
River Indian Community. Subjects provided written informed consent.
3.2.2.2 Analytical Measurements
The plasma glucose concentration was measured by the glucose oxidase
method (Beckman Glucose Analyser: Beckman, Fullerton CA) and insulin by
radioimmunoassay (Concept 4: ICN Biomedicals, Costa Mesa, CA). Homeostasis
Model Assessment Insulin Resistance Index (HOMA-IR) was calculated as
previously described (Gorzelniak et al 2002).
3.2.2.3 Biopsy Analysis
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11HSD1 activity, 11HSD1 and GRa mRNA and tissue Cortisol and cortisone
were analysed as described in chapter 2 (section 2.7). Recovery of tracer 3H-steroid
for tissue Cortisol and cortisone measurements averaged 61 ± 12%.
3.2.2.4 Statistical Analysis
All values are represented as mean ± SD unless otherwise indicated.
Statistical analyses were performed using the procedures of the SAS Institute (Cary,
NC, USA). Relationships between 11HSD1 activity and adipose or metabolic
variables were assessed either by Pearson correlation (using area under the curve for
the 11HSD1 reaction) or, where multiple covariates were assessed, by general linear
modeling. Throughout this chapter, where data were not normally distributed, these
were log transformed and distribution plots re-assessed to ensure a normal
distribution had been achieved. Where log transformation has been performed this is
indicated in the relevant tables (e.g. fasting insulin, 11HSD1 mRNA and tissue
Cortisol). Where 11HSD1 activity is modeled as the dependent variable, separate
time points of the 11HSD1 assay (3, 6, 20, 30 hours) were fitted in a repeated
measures design.
3.2.3 Results
3.2.3.1. Baseline characteristics and relation of adipose 11HSD1 activity to mRNA
levels and tissue Cortisol
Measures of adiposity (BMI, %fat, waist circumference), fasting plasma
glucose and insulin were comparable between the Pima and Caucasian groups (Table
3.1). Neither fasting plasma insulin nor HOMA-IR differed between Pimas and
Caucasians even after adjustment for sex, and %fat or BMI (data not shown). Ten
subjects (Caucasian 2 males, 1 female; Pima 3 males, 4 females) had impaired
glucose tolerance (IGT)(World Health Organisation 2004). All other subjects were
normal glucose tolerant (NGT). While glucose at 2 hours was higher in those with
IGT, other baseline variables were similar (%fat, BMI, waist, all P>0.5 vs. NGT)
including fasting glucose (NGT 4.79±0.39 mmol/1; IGT 5.06±0.61 mmol/1; P=0.2).
11HSD1 activity (area under curve for adipose biopsies at 3, 6, 20 and 30 hours





















Associations between 11HSD1 activity and mRNA
11HSD1 mRNA levels and in-vitro activity correlate in subcutaneous
adipose biopsies in a)American, b) Finnish, c) Swedish Cohorts.
11HSD1 mRNA levels were analysed by real time PCR and expressed
as a ratio against cyclophyllin mRNA. 11HSD1 activity is calculated as
area under the curve of % conversion of Cortisol to cortisone after
incubation for 3, 6, 20 and 30 h.
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0.51, P=0.003). This relationship was consistent across all of time points of the
activity assay (3, 6, 20, 30 hours; r=0.47, 0.49, 0.56, 0.60, respectively; P<0.01 for
all). When considered separately the relation of 11-HSD1 activity and mRNA levels
was present in both Pima Indians (r= 0.58, P=0.01) and Caucasians (r= 0.69,
P=0.02).
Intra-adipose concentrations of Cortisol (median[inter-quartile range]: 14.2[9.4-
25.8] nmol/kg) and cortisone (14.8 [5.0-21.4]nmol/kg) were similar (ratio of intra-
adipose Cortisol: cortisone 1.4[0.5-2.9]). There were no significant relationships of
11-HSD1 activity (r=0.13, P=0.49) or mRNA (r=0.30, P=0.11) to intra-adipose
Cortisol. Intra-adipose Cortisol: cortisone ratio showed no relationship to 11HSD1
activity or mRNA (assessed by Spearman correlation r=0.07 and -0.05, respectively,
P>0.5 for both).
3.2.3.2 Relationship ofadipose 11HSD1 to obesity andmetabolic variables
In all subjects combined, 11HSD1 activity was significantly associated with
BMI, %fat, waist circumference, fasting plasma glucose, fasting plasma insulin and
HOMA-IR (Table 3.2, Figure 3.2). When Pima Indians and Caucasians were
considered separately, positive associations between 11HSD1 activity and BMI,
%fat, waist, fasting plasma glucose, fasting plasma insulin and HOMA-IR were all
present (with r >0.5 and P<0.05) although this was not significant for %fat (r=0.52,
P=0.09) and glucose (r=0.43, P=0.18) in the isolated Caucasian group. In general,
similar but somewhat weaker relationships were observed with adipose 11HSD1
mRNA (Table 3.2). To dissect confounding effects in these relationships, 11HSD1
activity was modeled against continuous variables by repeated ANOVA. Either
fasting insulin (P=0.02) or HOMA-IR (P=0.0002) remained significant predictors of
11HSD1 activity in models also including %fat, sex, ethnicity (Pima vs Caucasian)
and waist circumference. Similarly either fasting insulin (P=0.02) or HOMA-IR
(P=0.01) were significant predictors of 11HSD1 mRNA (in models also including
%fat, sex, ethnicity and waist circumference). By contrast, in these models,
measures of adiposity (%fat or waist circumference) were not significant predictors
of 11HSD1 activity or mRNA (P>0.2 for all), indicating that the stronger
relationships were with insulin sensitivity rather than adiposity.
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Table 3.1: American Cohort; Subject Characteristics
Pima Caucasian P
N (male, female) 19(10,9) 12(7,5)
Age (years) 29.5 ±7.4 27.6± 8.1 0.51
BMI (kg/m2) 34.6± 6.7 36.6± 8.6 0.47
%fat 35.5± 5.6 34.1±7.7 0.57
Waist (cm) (n=17/10) 43.3± 3.9 42.6± 5.7 0.70
Fasting glucose (mg/dl) 90± 9 87± 7 0.41
2 hour glucose (mg/dl) 126+ 27 134± 30 0.46
Fasting insulin (mU/1) 45 [38-52] 38 [32-51] 0.40
11HSD1 activity (%.hours) 464± 345 496± 257 0.78
11HSD1 mRNA13 0.56 [0.40-0.94] 0.41 [0.24-0.60] 0.07
Tissue Cortisol (nmol/kg) 14.2 [9.3-22.4] 16.0 [10.7-43.4] 0.54
Tissue cortisone (nmol/kg) 15.3 [7.9-26.4] 10.2 [4.4-20.7] 0.50
Characteristics of Pima and Caucasian volunteers. Data are expressed as mean± SD
or median [inter quartile range], P= unpaired t test or Wilcoxon respectively.
a 11HSD1 activity- Area under curve for conversion Cortisol to cortisone at 3,6,20
and 30 hours.
^expressed as ratio of 11HSD1 to cyclophilin.
Table 3.2: American Cohort; Correlations of 11-HSD1 activity and mRNA vs.
metabolic variables
Activity mRNA Adipose Cortisol
BMI 0.68 0.34 0.29
%fat 0.48 0.15 0.22
waist (n=27) 0.52 0.26 0.21
Fasting glucose 0.43 0.19 -0.28
2 hour glucose 0.08 0.09 -0.19
Fasting insulin 0.60 0.42 0.37
HOMA-IR 0.70 0.46 0.30
Pearson correlation ( r) of adipose biopsy 11HSD1 activity (expressed as area under
curve for bioassay at 3,6,20 and 30 hours) or mRNA (normalized to cyclophilin as
reference standard) vs. metabolic variables with adjustment for sex. Values in bold
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Figure 3.2
American Cohort; Adiposity and metabolic variables vs. 11HSD1
activity
Relationship of 11-HSD1 activity to metabolic variables in 31 subjects
(see also Table 3.2). 11-HSD1 activity is defined as the area under the
curve for bioassay of 11-HSD1 adipose biopsies at 3,6,20 and 30 hours
of incubation.
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Ethnicity was not significantly related to 11HSD1 activity as a single predictor
(P=0.53) or in the above models. Overall Caucasians tended to have higher 11-
HSD1 mRNA levels as a single predictor (Table 3.1, P=0.07) and this was significant
in the above models (P=0.0007 in model with sex, %fat, waist and fasting insulin;
P=0.0005 in model with sex, %fat, waist and HOMA-IR).
No difference in 11HSD1 activity or mRNA was found in individuals with IGT
vs. NGT (P=0.71) even after adjustment for other covariates (sex, %fat, ethnicity; P
for effect of glucose tolerance status =0.68). In multivariate models fasting glucose
was not related to mRNA or 11HSD-1 (data not shown).
Gender was not related to 11HSD1 activity or mRNA either as a single
predictor (P=0.73, P=0.11 respectively) or after inclusion of %fat, fasting insulin or
HOMA-IR as additional predictors.
3.2.3.3. Relation of intra-adiposc Cortisol and cortisone to obesity and metabolic
variables
Correlations between intra-adipose Cortisol and anthropometric or metabolic
variables were generally positive, but only significant in the case of fasting insulin
(Table 3.2). Intra-adipose Cortisol was not significantly related to fasting insulin or
HOMA-IR in multivariate models (including %fat , gender and waist). Neither intra-
adipose cortisone nor cortisohcortisone ratios correlated with anthropometric or
metabolic variables (data not shown). There were no ethnic differences in intra-
adipose Cortisol or cortisone levels.
3.2.3.3. Relation ofGRa to obesity and metabolic variables
GRa mRNA was not significantly associated with central (WHR =-0.25) or
generalised (BMI=-0.07, %Fat=-0.18) obesity.
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3.3. Body Fat Distribution and Cortisol Metabolism in Healthy Finnish Men
3.3.1 Introduction
This study addresses in detail the relationships between Cortisol metabolism
and body fat distribution, in a group of healthy men in whom body fat distribution
and associated metabolic parameters have been carefully characterised, and include
assessment of liver fat content by magnetic resonance imaging (MRI) spectroscopy
and visceral fat mass by cross-sectional MRI. Accumulation of triglyceride stores in
selected adipose and extra-adipose sites is recognised increasingly as a determinant
of insulin sensitivity and its attendant cardiovascular risk. Metabolically adverse sites
for fat accumulation include visceral fat, skeletal muscle and liver (Bjorntorp
1991 ;Virkamaki et al 2001;Seppala-Lindroos et al 2002). Glucocorticoid excess (as
in Cushing's syndrome), results in accumulation of fat in selected adipose tissue
depots, especially in the face, nape of the neck, and visceral compartments (Ross &
Linch 1982). Anecdotal reports also suggest that glucocorticoid excess drives
triglyceride accumulation within the liver (Itoh et al 1997;Nanki et al 1999;Dourakis
et al 2002). In this study we assess intra-adipose glucocorticoid metabolism, by
assessment of 11HSD1 activity and mRNAs for 11HSD1, GR, H6PDH, 5a-
Reductase Type 1 and downstream target genes (LPL, HSL, PPAR-y, adiponectin,
resistin, angiotensinogen, aromatase and leptin) in subcutaneous adipose biopsies.




Men were recruited from occupational health services in Helsinki. The subjects
did not use any drugs and were healthy as judged by history and physical
examination, negative serology (for hepatitis A, B or C, or of autoimmune hepatitis),
and the absence of clinical features of inborn errors of metabolism or a history of use
of toxins or drugs associated with steatosis, except for moderate alcohol
consumpation (<20 g/day). Alcohol consumption was assessed by detailed history
and laboratory markers [serum 7-glutamyltranspeptidase, the aspartate
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aminotransferase (AST)/alanine aminotransferase (ALT) ratio, and mean corpuscular
volume]. Written informed consent was obtained. The experimental protocol was
approved by the ethical committee of the Helsinki University Hospital.
3.3.2.2 Body composition
Height, weight, waist and hip circumferences, and whole body composition by
bioimpedance plethysmography (Bio-Electrical Impedance Analysis System, Model
#BIA-101A, RJL Systems,MI) were measured after overnight fasting as previously
described (Tukkainen et al 2002). In addition, body fat distribution was measured in
the liver by MRI proton spectroscopy using methylene signal intensity and in the
abdomen by cross-sectional MRI using data from sixteen 10 mm slices (Tukkainen et
al 2002).
3.3.2.3 In vivo insulin sensitivity ofglucose production and utilization
At 0800 h after an overnight fast, blood pressure was recorded and basal blood
samples were obtained for the measurements in Table 1, and subjects underwent a
euglycaemic hyperinsulinaemic clamp as previously described (DeFronzo et al
1979;Seppala-Lindroos et al 2002). Glucose production and disposal were measured
by infusion of [3-3H]glucose in a primed (20 pCi) continuous (0.2 pCi/min) fashion
for a total of 360 min (Ryysy et al 2000). After 120 minutes, insulin was infused in a
primed-continuous (0.3 mU/kg-min) fashion. Plasma glucose was maintained at 5
mmol/l (90 mg/dl) until 360 min using a variable rate infusion of 20 % glucose.
Glucose kinetics and % suppression of free fatty acids from baseline were calculated
during the final 60 min of the clamp. Serum free insulin concentrations were
measured using radioimmunoassay (Pharmacia Insulin RIA kit, Pharmacia, Uppsala,
Sweden) after precipitation with polyethylene glycol. Plasma glucose concentrations
were measured in duplicate with the glucose oxidase method using a Beckman
Glucose Analyzer II (Beckman Instruments, Fullerton, CA). Serum free fatty acids
were measured using a fluorometric method. Serum lipids were measured as
previously described (Tukkainen et al 2002).
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3.3.2.4 Intra-adipose Cortisol metabolism
A randomly selected subgroup of subjects who consented to providing a biopsy
reattended between 0800-1200 h on another day, when a ~500 mg subcutaneous
adipose biopsy was obtained under local anaesthesia through a 2-3 cm incision from
the para-umbilical anterior abdominal wall. Subcutaneous fat was frozen
immediately in two aliquots in liquid nitrogen. Adipose 11HSD1 activity, mRNA for
11HSD1 and downstream targets was measured as described in chapter 2.
3.3.2.5 Statistical analyses
Areas under curves for 11HSD1 activity in adipose in vitro were calculated
using the trapezoidal rule. In all sections of this chapter Variables were log
transformed if necessary to obtain a normal distribution, as indicated in the tables.
Pearson correlation analyses were performed to identify associations. Confounding
between associations was addressed using forward stepwise mutliple linear
regression analysis with variables entering the final model if F>1.0. All data are




Participating men were aged 22-57 years with a wide range of body mass index
(20.6 - 35.6 kg/m2), waist/hip ratio (0.85 - 1.1), whole body fat (11.2 - 31.0 %),
visceral fat (1423 - 7025 cm3), subcutaneous abdominal fat (1302-4650 cm3), and
liver fat (1 - 41%). Associations between body composition variables are shown in
Table 3.3. Data are shown for subjects above or below the median for each
measurement of body composition; however, statistical comparisons were by
Pearson correlations. Body composition did not change significantly with increasing
age, but subjects with generalised or visceral obesity tended to be older. Increased
whole body fat was associated with higher body mass index and liver fat content.
Increased visceral fat was associated with higher body mass index. However,
waist/hip ratio correlated more strongly with MRI measurements of subcutaneous
abdominal fat mass (r=0.39, p=0.05) than with visceral fat mass (r=0.20, p=0.35).
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3.3.3.2 Associations ofCortisol metabolism and body composition
Results of Pearson correlations are in Table 3.3b). Increasing whole body fat
was associated with increased 11HSD1 activity in adipose tissue with non-significant
trends for increased adipose 11HSD1 mRNA. Similar associations of glucocorticoid
parameters were observed with waist circumference, waist/hip ratio, and
subcutaneous abdominal fat by MRI (data not shown). In contrast, visceral fat mass
was not associated significantly with any indices of Cortisol metabolism. In men with
higher liver fat content, there was no difference in adipose 11HSD1 activity or
mRNA.
For the variables for which associations were identified in Pearson correlation
analyses in Table 3.3, we explored the relative influence of fat accumulation in
different sites. We performed stepwise multiple regression analyses of indices of
Cortisol metabolism with % body fat, visceral fat, subcutaneous abdominal fat, and
liver fat as independent variables.Values are beta correlation coeffients (r). Whole
body % fat was consistently the best predictor of indices of increased adipose
11HSD1 activity (r= 1.23, p<0.01). Liver fat accumulation was independently
associated with decreased adipose 11HSD1 (r= -0.63, p<0.05). When corrected for
the effect of total body fat and liver fat, visceral fat mass was inversely associated
with adipose 11HSD1 activity (r=-0.24, p=NS).
3.3.3.5 Adipose Biopsy analysis; associations with parameters of obesity, insulin
resistance, and downstream targets
Adipose 11HSD1 activity and mRNA were closely correlated (r=0.77,
p<0.001, figure 3.1). Results are summarised in table 3.4. Generalised obesity was
associated positively with 11HSD1 activity, 11HSD1 mRNA (trend only), H6PDH
mRNA and negatively with GRa mRNA. Central obesity (waist hip ratio) was
similarly associated with 11HSD1 activity and GRa mRNA. GRa mRNA was
negatively associated with log fasting insulin, and positively associated with
Angiotensinogen mRNA. 5a-reductase type 1 mRNA was positively associated with
mediators of lipolysis/ adipogenesis (HSL, LPL and PPAR-y), and aromatase.
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3.4 Local and Systemic Impact of Transcriptional Upregulation of llp-
Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue in Human Obesity in
Healthy Swedish Volunteers
3.4.1 Introduction
In this Swedish cohort of men and women, previous investigations had shown
increased ex vivo 11HSD1 activity in subcutaneous adipose tissue associated with in
vivo obesity and insulin resistance (Rask et al 2001;Rask et al 2002). Using these
biopsies, we investigated this further by measuring 11HSD1 mRNA and mRNAs for
other mediators of glucocorticoid metabolism (H6PDH and 5a-Reductase type 1),
and putative glucocorticoid regulated adipose target gene expression
(angiotensinogen, leptin, HSL, LPL, PPAR-y adiponectin, restitin, aromatase). We
have further examined the impact on intra-adipose Cortisol concentrations, and
systemic measurements of Cortisol metabolism.
3.4.2 Methods
3.4.2.1 Subjects
Subjects were recruited from a population-based study in northern Sweden, the
WHO-conducted MONICA Project. From an original random sample of 2815
women and men, 41 Caucasian women and 40 men were selected to represent high
and low fasting insulin concentrations and a wide range of BMI. Investigations in
. these groups have been reported previously (Rask et al 2001;Rask et al 2002). A
subgroup of these subjects, selected at random (n=16 females, n=16 males), attended
in the morning after an overnight fast. After local anaesthetic injection of prilocaine
(lOmg/ml Citanest, Astra, Sodertalje, Sweden) in the skin area to the right of the
umbilicus, approximately 1.5cm2 sc fat was excised through a 2-3cm incision.
Subcutaneous fat was frozen immediately in two aliquots at -70°C.
Diabetes mellitus, liver, renal and thyroid disease were excluded by routine
laboratory tests. In the pre- and peri-menopausal women, investigations were
performed in the follicular phase of the menstrual cycle (5-10d after starting
menstruation). These studies were approved by the ethics committee of Umea
University Hospital, and written informed consent was obtained.
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3.4.2.2 Previous Clinical and Biochemical Measurements
Measurements, as described previously, (Rask et al 2001;Rask et al 2002)
included baseline anthropometry, blood pressure and body composition. Insulin
sensitivity was measured using the euglycaemic hyperinsulinaemic clamp technique.
Cortisol metabolites were measured in 24 hour urine samples by gas chromatography
and electron impact mass spectrometry. Liver 11HSD1 activity was assessed in vivo
by conversion of oral cortisone to Cortisol (measure in plasma) on first pass through
the liver. Subjects took oral dexamethasone (3.5ug/kg body weight) at 2300h, fasted
overnight and attended at 0830h for intravenous cannulation and oral cortisone
acetate 25mg. Plasma samples were taken over 4 hours to measure kinetics of
Cortisol appearance as previously described (Rask et al 2001 ;Rask et al 2002).
3.4.2.3 Biopsy Analysis
Adipose 11HSD1 activity, adipose mRNAs, intra-adipose Cortisol and
cortisone levels were measured as described in chapter 2. Extraction efficiency for
intra-adipose Cortisol/ cortisone was assessed by recovery of the 3H-steroid. Steroid
extraction efficiency was 28.4% ± 1.2% (mean±SEM).
3.4.2.4 Statistics
Data are mean ± SEM unless otherwise stated. Where indicated, data were
naturally log transformed to obtain a normal distribution for parametric testing.
Areas under the curve for 11HSD1 activity in vitro and conversion of cortisone to
Cortisol in vivo were calculated using the trapezoidal rule. Results in men and
women were compared by Student's t-tests. Multiple regression analyses were
employed to adjust for the influence of gender. To assess relationships between
adipose mRNAs, adjustment was also made for BMI, where appropriate.





Characteristics of participants are shown in Table 3.5. Men had lower % body
fat, lower urine cortisol/cortisone metabolite ratios, HDL cholesterol, lower
angiotensinogen and leptin mRNA levels and higher waist hip ratios than women.
H6PDH, 5a-Reductase Type 1, HSL, LPL and aromatase mRNA levels were higher
in men (Table 3.5).
3.4.3.2 Adipose 11HSD1
Adipose 11HSD1 activity and mRNA levels were closely associated with each
other (Figure 3.1) and with parameters of obesity and insulin resistance (Table 3.6,
Figure 3.3). To minimize potential confounding by effects of gender, relationships
with obesity and other metabolic variables were adjusted for gender in multiple
regression analyses. Further, BM1 was chosen as the measurement of obesity in
multiple regression because it was distributed similarly between men and women
(unlike waist circumference, waist/hip ratio, or % fat). Results are shown in Table
3.6. Higher 11HSD1 activity was associated with both obesity and fasting
hyperinsulinaemia, while higher 11HSD1 mRNA was significantly associated with
obesity alone. In multiple regression analyses, the influence of BMI on adipose
11HSD1 activity was adjusted for insulin sensitivity and vice versa; associations of
BMI and insulin sensitivity with 11HSD1 activity or mRNA could not be shown to
be independent of each other in these models (data not shown). Neither 11HSD1
activity nor mRNA associated with in vivo urinary cortisol/cortisone metabolites
ratios. 11HSD1 mRNA was positively associated with aromatase mRNA expression
(0.37, p<0.05).
3.4.3.2 Adipose H6PDH/ 5a-Reductase Type 1 mRNAs
Results are summarised in table 3.6. H6PDH mRNA was positively associated
with HDL cholesterol and systolic blood pressure but no other parameters of obesity
or insulin sensitivity. H6PDH was positively associated with mRNA expression of
Leptin, HSL, Adiponectin and Resistin. 5a-Reductase Type 1 mRNA was

























































Swedish Cohort; Adiposity and metabolic variables vs. 11HSD1
activity and mRNA
Associations of 11HSD1 mRNA (a and c) or 11HSD1 activity (b and d)
with Body Mass Index (BMI; a and b) or fasting plasma insulin (c and d)
in subcutaneous adipose biopsies in men (open circles, n=13) and women
(filled squares, n=14). 11HSD1 mRNA levels were analysed by real time
PCR and expressed as a ratio against cyclophyllin mRNA. 11HSD1
activity was calculated as area under the curve of % conversion of Cortisol
to cortisone after incubation for 3,6, 20 and 30 h.
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Table 3.5: Swedish Cohort; comparison of male and female subjects
Male (n=16) Females (n=16)
Age (y) 53.4±2.5 56.8±2.8
BMI (kg/m2) 26.5±0.8 25.3±0.9
WaistcHip Ratio 0.9±0.01** 0.9±0.02**
% Fat 26.9±0.9* 31.74±1.6*
Fasting 0900h blood results:
Glucose (mmol/1) 4.7±0.1 4.5±0.2
Insulin (mU/1) 7.8±1.3 7.4±1.5
Triglycerides (mmol/1) 1,8±0.4 1.3±0.1
Total cholesterol (mmol/1) 5.2±0.2 5.9±0.4
HDL cholesterol (mmol/1) 1.1±0.08* 1.4±0.09*
Cortisol (nmol/1) 293±30 369±28
Insulin sensitivity index (euglycaemic clamp)" 6.7±0.8 7.9±1.0
Systolic blood pressure (mmHg) 135±5 139±6
Diastolic blood pressure (mmHg) 82±3 81 ±4
Urine THFs/THEb 1.2±0.1** 1.92±0.2**





(area under curve 0-30%. h) (n=29, 16m, 13f)





Intra-adipose cortisone (nmol/kg) (n=27, 13m, 14f) 293±111 162±43
Adipose mRNAs (n=27.13m. 14f):
11HSD1 1.61 ±0.13 1.47±0.14
H6PDH 3.00±0.6* 1.61±0.3*
GRcc 1.1 ±0.1 1.12±0.04







Adiponectin 1.01 ±0.2 0.71 ±0.1
Aromatase 2.14 ±0.4* 1.11±0.2*
Data are mean ± SEM a mg glucose.kg"1.min"1 per mU/1 of insulin x 100 b THFs=
5atetrahydrocortisol + 5Ptetrahydrocortisol: THE=tetrahydrocortisone * p<0.05 **p<0.01 between
men and women by Student's t tests
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3.4.3.4 Glucocorticoid Receptor mRNA
Glucocorticoid receptor alpha (GR-a) was the predominant isoform in human
adipose (mean 26.7 cycles in real time PCR versus 37.5 cycles for GR-(3). GR-a
mRNA showed no significant correlations with parameters of obesity or
hyperinsulinaemia (although trends were towards inverse correlations)(Table 3.6).
To test a possible interaction between 11HSD1 and GRa expression in predicting
obesity and insulin resistance, multiple regression analyses were performed. These
did not suggest any interaction and did not attenuate the relationships shown in Table
3.6 (data not shown). GR-a mRNA was positively associated with HSL and LPL
mRNAs.
3.4.3.3 Intra-Adipose Cortisone and Cortisol
Tissue Cortisol and cortisone concentrations are shown in Table 3.5. Values
were log transformed for analysis. Neither correlated with adipose 11HSD1 enzyme
activity or mRNA. Higher intra-adipose Cortisol was associated with higher plasma
Cortisol levels after oral cortisone administration (Table 3.6), and non-significantly
with Cortisol levels at 0900 (SBC=0.41, p=0.06) and after overnight dexamethasone
(SBC=0.34, p=0.18).
3.4.4 Combined results from Finnish and Swedish Cohorts
Data from Swedish and Finnish Cohorts were combined to further assess
relationships between determinants of glucocorticoid metabolism and downstream
targets. The American cohort was not included as there was not enough cDNA in this
group to measure downstream target mRNAs. Combining the cohorts results in
increased subject numbers (power) and allowed us to assess which relationships are
most robust and remained consistent across cohorts. Results are summarised in table
3.8. Main findings were as follows. 11HSD1 activity and mRNAs for 11HSD1 and
aromatase were positively associated with generalised obesity (BMI or %fat).
11HSD1 mRNA was also associated with central obesity (waist-hip ratio). GR-a
mRNA was negatively associated with all aspects of obesity (BMI, %fat and waist
hip ratio). Gender differences shown are discussed in section 3.4.3.1. We found
differences in mRNA expression between cohorts (higher 11HSD and lower HSL
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and GRa mRNAs), which may reflect methodological rather than biological
differences, since real time PCR on each cohort was performed in separate batches,
using a relative standard curve of diluted cDNA pooled from within each cohort, so
that, although cohorts may differ in apparent absolute mRNA levels, this may reflect
a systematic difference in the standard curves in the two cohorts rather than selective
differences in these mRNAs. For this reason multiple regression analysis adjusted for
differences between cohorts (in addition to gender) where appropriate in multiple
regression analysis of combined cohort data.
3.5 Discussion
3.5.1 Adipose Glucocorticoid Metabolism in Human Obesity
A number of recent studies have supported a potential role of glucocorticoid
metabolism by adipose tissue in lipid and glucose homeostasis. In these cross
sectional studies we confirm clear associations of subcutaneous adipose 11HSD1
activity and mRNA levels with indices of obesity, and show additional relationships
with metabolic variables reflecting insulin sensitivity.
The concept of tissue-specific dysregulation of 11HSD1 activity in human
obesity is now supported by a series of studies. It arose from observations that
conversion of oral cortisone to plasma Cortisol is impaired in obese men (Stewart et
al 1999;Rask et al 2001) consistent with impaired hepatic 11HSD1, yet urinary ratios
of cortisol/cortisone metabolites are highly variable (Andrew et al 1998;Stewart et al
1999;Fraser et al 1999;Rask et al 2001;Rask et al 2002) suggesting compensatory
differences in extra-hepatic 11HSD activity. The concept was supported by
increased 11HSD1 activity in adipose of Zucker obese rats and ob/ob obese mice
associated with reduced 11HSD1 activity in livers in these animals (Livingstone et al
2000). Our findings of increased 11HSD1 in adipose in human obesity are consistent
with a parallel study by Paulmyer-Lacroix et al (Paulmyer-Lacroix et al 2002) and
have subsequently been confirmed by others (Engeli et al 2004;Kannisto et al 2004).
The current data confirm the magnitude of this increase in 11HSD1 activity,
demonstrate a close relationship of 11HSD1 activity and mRNA from the same
biopsies, as has previously been seen in studies in rodents (Livingstone et al 2000),
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and support higher 11HSD1 activity and gene transcription in adipose tissue in
obesity. By contrast one study, examining biopsy material obtained during intra¬
abdominal surgery, has recently reported no relationship of 11HSD1 mRNA levels in
subcutaneous adipocytes to BMI and an inverse relationship of 11HSD1 activity (in
cultured preadipocytes) to BMI (Tomlinson et al 2002). There are notable
differences in the studies. 11HSD1 activity and mRNA may have been altered by the
stress of major surgery. 11HSD1 activity was measured in cells cultured to
confluence rather than from the primary biopsy material, as in our study. The close
relationship of mRNA and 11HSD1 activity in all three studies gives support to our
results reflecting a true measure of adipose enzyme activity.
The Finnish study gives a more detailed description of altered Cortisol
metabolism in association with regional fat accumulation. Increased abdominal
subcutaneous adipose 11HSD1 (which predicts increased Cortisol regeneration from
cortisone within fat) and increased total Cortisol metabolite excretion were associated
with a higher proportion of whole body fat but not with preferential fat accumulation
in either visceral, subcutaneous abdominal, or hepatic depots.
In humans, it has been hypothesised that there is a syndrome in which
increased intra-adipose generation of Cortisol by 11HSD1 in visceral fat leads to
central obesity and the metabolic syndrome, in what has been described as
'Cushing's disease of the omentum' (Bujalska et al 1997). We observed however that
adipose 11HSD1 seemed to be associated more with generalised than central obesity
and used detailed MRI measurement in the Finnish study to further address this
paradox. This confirmed a lack of association with visceral adipose accumulation
and strong associations with generalised fat accumulation.
Studies in primary culture suggest that 11HSD1 is more active in visceral than
subcutaneous adipocytes (Bujalska et al 1999),although this may not hold in freshly
isolated tissue (Paulmyer-Lacroix et al 2002), and there is as yet no direct evidence
that visceral 11HSD1 is increased in obesity (Tomlinson et al 2002). Rather, it is
studies of subcutaneous adipose tissue, like these, which have consistently shown
increased 11HSD1 activity and mRNA in obese subjects (Rask et al 2001;Paulmyer-
Lacroix et al 2002;Rask et al 2002;Wake et al 2003;Lindsay et al 2003) predicting
either generalised (body mass index or total % body fat) or central (waist/hip ratio or
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waist circumference) obesity. However, waist circumference and waist/hip ratio
provide imprecise indices of visceral fat accumulation. Indeed, in the current data
waist/hip ratio was more closely related to abdominal subcutaneous fat than visceral
fat (Table 3.3). One previous small study used CT scans of the abdomen to quantify
visceral fat but was not definitive as it reported only a lack of association between
visceral/subcutaneous fat ratio with the urinary cortisol/cortisone metabolite ratio in
patients receiving Cortisol replacement therapy (Tiosano et al 2003); this urinary ratio
is an inadequate indicator of 11HSD1 activity. Thus, whether variations in
subcutaneous adipose 11HSD1 are associated with variations in visceral fat
accumulation has not been examined previously. The current results show that it is
total body fat, not visceral fat mass, which is associated with increased subcutaneous
adipose 11HSD1 activity. Increased adipose 11HSD1 activity in human obesity may
be invoked as a cause of 'Cushing's disease of the adipose' but not yet of 'Cushing's
disease of the omentum'.
In mice with transgenic over-expression of 11HSD1 in adipose, plasma
corticosterone levels are unaltered but intra-adipose corticosterone levels are elevated
~2-fold (Masuzaki et al 2001). To test whether the adverse metabolic consequences
of increased adipose 11HSD1 could similarly be attributed to increased intra-adipose
generation of Cortisol we extracted glucocorticoids from adipose biopsies.
Assessment of adipose regeneration of Cortisol from cortisone in vivo is difficult; a
previous attempt using arteriovenous sampling in large numbers of patients showed a
strong trend that was not quite statistically significant (Katz et al 1999). The lack of
relationship between adipose 11HSD1 and concentrations of intra-adipose Cortisol or
cortisone may be explained in a number of ways. Firstly, extraction of steroids from
human adipose biopsies is technically demanding and application to small samples is
novel. Second, variations in plasma Cortisol, including those relating to the stress of
the biopsy may contribute to the adipose pool. (Unfortunately concomitant plasma
samples were not available to allow assessment of this). In the transgenic mice with
adipose 11HSD1 overexpression, samples were obtained during the diurnal nadir of
glucocorticoid secretion (Masuzaki et al 2001), when 11HSD1 is putatively more
important in maintaining intra-cellular glucocorticoid levels (Seckl & Walker 2001).
In these studies, biopsies were obtained during the diurnal peak of Cortisol secretion
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when the influence of circulating Cortisol may be more important. In that light we
consider our examination of intra-adipose Cortisol exploratory and clearly far from
definitive. Nevertheless, the American study did show positive relationships
between intra-adipose Cortisol and most anthropometric and metabolic indices of
obesity and insulin resistance. In the Swedish study this was not the case but intra-
adipose Cortisol correlated with plasma Cortisol levels taken at other times suggesting
that measurements may have been influenced primarily by stress at the time of taking
the biopsy. These relationships deserve further exploration to establish if they can be
attributed to variations in adipose 11HSD1 and/or to increased plasma Cortisol,
which has been observed in subjects with the metabolic syndrome (Phillips et al
1998;Rosmond et al 1998;Walker et al 2000). Finally these studies give no
indication of the mechanisms leading to elevated adipose 11HSD1 in the metabolic
syndrome. We explore potential regulators of 11HSD1 which may mediate
dysregulation in obesity through further in vivo studies in chapters 4 and 5.
3.5.2 Additional Determinants of Glucocorticoid Action; GR, H6PDH and 5a-
Reductase
Sub-cutaneous adipose GRa mRNA was negatively associated with parameters
of generalised and central obesity in all studies, but this association was only
significant in the Finnish cohort. Reduction in GR may limit glucocorticoid signaling
and downstream metabolic consequences of increased 11HSD1 in obesity. The
differences in 11HSD1/ GR balance between cohorts cannot be explained by gender
alone, and may reflect different genetic or environmental backgrounds or minor
differences in the biopsy protocols. To get a feel for the overall balance of 11HSD1
vs GR, we combined data form the Swedish and Finnish studies (n=46). In this
combined dataset, central adiposity (measured by waist:hip ratio) was positively
associated with 11HSD1 mRNA (r=0.35, p<0.05) and negatively associated with
GRa mRNAs (r=-0.30, p<0.05) in subcutaneous adipose tissue. A difference in
waist:hip ratio of 0.1 was associated with a ~34% increase in 11HSD1 mRNA and a
~10% reduction in GRa.
H6PDH generates NADPH, a cofactor required for 11HSD1 reductase activity
to convert cortisone into Cortisol (Draper et al 2003;Banhegyi et al 2004), and is co-
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localised with 11HSD1 in the lumen of the endoplasmic reticulum. Recent data
suggest an intimate association between these enzymes which may explain why
11HSD1 functions predominantly as a reductase in vivo but is bi-directional when
liberated from its intracellular environment. Complete loss of H6PDH, such as has
been described in the rare syndrome of 'cortisone reductase deficiency' results in
markedly impaired 11HSD1 reductase activity (Draper et al 2003). However,
whether subtle variations in H6PDH provide physiological control over Cortisol
generation remains to be established. To date, H6PDH has not been studied
extensively in adipose tissue and its regulation is uncertain. In the Finnish cohort,
H6PDH mRNA was positively associated with %Fat and in the Swedish cohort with
potential glucocorticoid targets genes Leptin, HSL, Adiponectin and Resistin. Whilst
intriguing, this should be interpreted with caution as these findings were not
consistent across cohorts. Nonetheless these associations suggest that H6PDH may
be more than a constitutive supplier of cofactor. Indeed, its expression has been
shown to vary according to adipocyte differentiation state, emphasising that its
potential importance deserves further dissection.
Previous in vitro and in vivo studies have demonstrated the presence of 5a-
reductase activity (but have not assessed mRNA) in adipose tissue, which does not
differ with adipose site and does not appear to be potently regulated by
glucocorticoids (Killinger et al 1990). We have demonstrated that adipose
5a-reductase activity can be attributed to the type 1 isozyme but its expression was
not consistently associated with generalised or central adiposity. 5a-reductase type 1
is traditionally considered as an androgen-activating enzyme (chapter 6), but is most
highly expressed in liver where it makes a major contribution to metabolism of
Cortisol. Recent data show that the 5a-reduced metabolites of glucocorticoids are not
inert, but in fact can bind and activate GR both in vitro and in vivo (Mclnnes et al
2004). Thus, it is possible that there is a component of glucocorticoid action in
adipose which is associated with increased 5a-reductase type 1 activity (discussed
further in chapter 6). It may therefore be either glucocorticoid or androgen receptor
activation which account for the links between 5a-reductase type 1 and downstream
targets (LPL and PPARy) (see 3.5.3). There is a risk, particularly in the inter-analysis
of adipose mRNAs, that the results are subject to bias from multiple statistical
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testing. Bonferroni corrections were not used here, but we accept that results with a
marginal p values should be interpreted with caution. We have therefore
concentrated in our discussion on findings that were consistently found in all cohorts
or with highly significant results suggesting a 'real' effect.
3.5.3 Downstream Effects of Altered Adipose Glucocorticoid Metabolism
Angiotensinogen is produced in the liver and adipose tissue. Animal studies
suggest its production is glucocorticoid-regulated and contributes to obesity-induced
hypertension (Masuzaki et al 2001 ;Massiera et al 2001;Hainault et al
2002;GorzeIniak et al 2002;Paterson et al 2004), but human studies show
inconsistent relationships of adipose angiotensinogen expression with obesity (Van et
al 2000a;Van et al 2000b;Giacchetti et al 2002). We found that subcutaneous adipose
angiotensinogen levels are higher in females (consistent with well recognized
oestrogenic regulation) but show no relationship with adipose 11HSD1, or
parameters of obesity or blood pressure. Visceral adipose tissue was not assessed in
this study and may be the more abundant adipose source of angiotensinogen. GRa
mRNA was associated with angiotensinogen mRNA, but only in the Finnish cohort.
Adipose leptin synthesis and secretion is increased by exogenously
administered glucocorticoids in vitro and in vivo (Leal-Cerro et al 2001). Adipose
specific transgenic overexpression of 11HSD1 in mice leads to substantial increases
in adipose leptin mRNA and serum leptin (Masuzaki et al 2001). We demonstrated
higher adipose leptin mRNA levels in women. This gender difference is well
recognised and thought to be androgen dependent (Soderberg et al 2001). Leptin
mRNA was positively associated 11HSD1 activity and mRNA levels but was not
significant after correction for BMI.
In vitro studies suggest that aromatase is glucocorticoid regulated. There was a
positive trend between 11HSD1 and aromatase in these studies but this was not
significant when adjusted for BMI. Aromatase is further discussed in chapter 6.
Glucocorticoids regulate lipolysis and adipogenesis in vitro (Ringold et al
1986;Ottosson et al 1994;Samra et al 1998;Anderson et al 2002;Dang et al
2002;Palin et al 2003). The principal correlations here were of H6PDH with leptin
and HSL, and of 5a-reductase 1 with LPL and PPARy (these relationships persist
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after combining the Swedish and Finnish datasets (r=0.49, p<0.01 and 0.36, p<0.05
respectively). Interestingly, H6PDH expression was associated with mRNA
expression of mediators of insulin sensitivity/ resistance, adiponectin and resistin. As
this relationship was only present in the Swedish cohort however its importance is
uncertain.
3.6 Summary
Obesity is associated with widespread changes in glucocorticoid metabolism,
namely activation of the HPA axis, flattening of the diurnal Cortisol rhythm,
increased Cortisol clearance and reduced hepatic Cortisol activation (via 11HSD1).
We now demonstrate changes in adipose glucocorticoid metabolism, namely
increased 11HSD1 activity and mRNA levels in generalised obesity which is
associated with insulin resistance in both men and women. Whether these
relationships persist in visceral adipose, which is arguably the most metabolically
active fat depot, remains unknown. The importance of adipose 11HSD1 as a
functional mediator of metabolic complications also remains uncertain. These studies
suggest that the downstream impact of Cortisol generation in adipose may be limited
by compensatory changes in GR expression. Further although these studies show
clear associations between I1HSD1 and measures of insulin resistance, it has been
difficult to identify specific glucocorticoid regulated downstream target mRNAs or
to prove causality in these relationships. The real impact on glucocorticoid-
dependent processes in vivo, will undoubtedly best be assessed by the use of new
technologies such as microarray and the development of specific inhibitors of
11HSD1 (Alberts et al 2002).
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Chapter 4
ACUTE REGULATION OF CORTISOL METABOLISM BY METABOLIC
SIGNALS: INSULIN AND LIPID
4.1 Introduction
Chapter 3 clearly demonstrates increased adipose 11HSD1 in obesity, but
does not speculate on the cause of up-regulation. In the next 3 chapters, we explore
potential regulators of tissue 11HSD1 activity. Regulation of 11HSD1 mRNA in
animal and cell models by high fat feeding (Morton et al 2004a), insulin (Napolitano
et al 1998;Handoko et al 2000;Tomlinson et al 2001), and PPAR/ LXR agonists
(Berger et al 2001;Stulnig et al 2002), and putative control of enzyme direction by
NADPH generation (by hexose-6-phosphate dehydrogenase)(Banhegyi et al 2004),
suggest a key role for 11HSD1 in the adaptive response of adipose to altered
nutrition. Further, maladaptive dysregulation may underlie increased adipose
11HSD1 in human and rodent obesity. However, 11HSD1 regulation is tissue-
specific, and has not been studied in human adipose in vivo. Further, the metabolic
clearance rate for Cortisol is increased in obese subjects (Andrew et al 1998;Rask et
al 2002). Our group has attributed this to increased A-ring reduction of Cortisol by
5(3- and 5a-reductase enzymes. A-ring reductases may also be regulated by
nutritional factors (Tsilchorozidou et al 2003) and 5P-Reductase, a key enzyme also
involved in cholesterol and bile acid biosynthesis, is thought to be regulated by
substrate availability.
In this study we speculate that 11HSD1 may be acutely responsive to changes
in dietary factors and mediate cellular responses to eating. This is supported by
evidence that dietary lipid regulates adipose 11HSD in short term animal studies
(Morton et al 2004b) and in recent studies within our laboratory insulin appears to
cause very acute down-regulation of adipose 11HSD1 (Sandeep et al 2005). On this
background, we assessed acute regulation of Cortisol metabolism by nutritional
factors in vivo, in 9 healthy male volunteers specifically in response to
hyperinsulinaemia, and hyperlipidaemia; both being likely regulators as suggested by
the background evidence. Adipose 11HSD1 activity was determined by intra-
adipose microdialysis, and whole body Cortisol metabolism and liver A-ring
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reductases by intra-venous (9,11,12,12-2H4) Cortisol tracers (as described in chapter
2).
This chapter specifically aimed to determine i) Is adipose 11HSD1 acutely
regulated in vivo by hyperinsulinaemia and hyperlipidaemia and mediated by
changes in enzyme directionality? ii) Is whole body Cortisol metabolism and
clearance (via 5a- and 5P-Reductase) regulated by nutritional factors? and iii) Is
regulation of 11HSD1 by insulin and glucose transcriptional or post-transcriptional?
The later aim is assessed using in vitro studies in primary adipocyte cultures.
4.2. Methods
4.2.1 Study Design & Protocol (figure 4.1)
Nine healthy men (BMI 20-30kg/m2) were recruited as discussed in chapter 2.
Volunteers participated in a random-order 3-phase crossover single-blind study
comparing Cortisol metabolism during: (i) intravenous insulin and glucose infusion;
(ii) intravenous lipid infusion; and (iii) placebo saline infusion. The study order was
randomized and balanced and phases were separated by 7-14 days. In order to study
the acute time course of effects of hyperinsulinaemia and hyperlipidaemia,
(9,11,12,12-2H4) Cortisol tracers were infused to steady state before these
manipulations were introduced. The use of intravenous deuterated Cortisol tracers
was developed by Andrew et al (Andrew et al 2002) and the justification for use as a
mean of in vivo assessment of glucocorticoid metabolism in these acute regulation
studies is discussed in section 2.4.5.
In each phase, volunteers attended the Clinical Research Facility after
overnight fast. To avoid discomfort from prolonged fasting, subjects were given a
standard light breakfast at 7.00am, in anticipation that any post-absorptive effects
would have passed before steady state tracer measurements were made and
interventions began ~5 hours later. Three intravenous cannulae were inserted: one for
sampling arterialized blood was placed in a dorsal hand vein kept under a heated pad;
an antecubital vein was cannulated in each arm for infusions. After cleaning with
Betadine (SSL, Knutsford, UK) and injection of local anaesthetic (5mls Lignocaine
1%, Braun, UK), two microdialysis cannulae (containing 20kDa-permeable
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fat, approximately 10cm lateral to the umbilicus on each side, as previously
described in chapter 2.
At time zero (~8.30am) a primed intravenous infusion of Cortisol (20%
9,11,12,12- H4-cortisol and 80% hydrocortisone-21-succinate) was commenced (3.6
mg priming bolus then continuous 1.74 mg/h infusion)(Andrew et al 2002;Basu et al
2004;Basu et al 2005;Sandeep et al 2005;Andrew et al 2005). Through separate
microdialysis cannulae (Sandeep et al 2005), intra-adipose infusions were
3 3commenced of (i) 1,2,6,7-" FL-cortisol (50 nmol/1) and (ii) 1,2- H2-cortisone (67
nmol/1) at rates of 0.3 ul/min. After 3.5 hours, a further intravenous infusion was
commenced with either: (i) soluble human insulin (0.8 mU/kg/min) with variable rate
20% dextrose infusion to maintain arterialised blood glucose of 5 mmol/1; (ii)
Intralipid 20% (Intralipid™, Kabivitrum Inc., California and Stockholm)(30 ml/h for
15 min then 50 ml/m2/h); or (iii) 0.9% saline as placebo control (same rate as
Intralipid). Measurements continued for a further 3.5 hours. Volunteers were given
200mls of water to drink every hour to encourage regular bladder emptying.
Arterialized blood glucose was measured every 5 min using a glucometer
(Roche Accu-Check, Advantage 2). Arterialized blood samples were obtained at
intervals indicated in the Figures (summarized in Figure 4.1), plasma was separated
promptly and stored at -80C. Urine was collected at baseline and then every hour for
analysis of tracer steroid metabolism, the volume recorded and aliquots stored at -
20C. Microdialysis microvials were changed every hour and dialysate stored at -80C.
4.2.2 Laboratory assays
Isotopomers of 9,11,12,12-2H4-cortisol (D4-cortisol), 9,12,12-2H3-cortisone (D3-
cortisone) and 9,12,12-2H3-cortisol (D3-cortisol) were measured in plasma and urine,
and Cortisol kinetics calculated as described in sections 2.4.5 and 2.8. Microdialysis
cannulae were changed hourly and % conversion of cortisone to Cortisol (reductase
activity) or Cortisol to cortisone (dehydrogenase activity) per hour was calculated
(section 2.4.3). Insulin, glucose, triglycerides and free fatty acids were measured in
plasma (see section 2.6).
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4.2.3 Statistics
Sample size calculations were based on the main outcome measure (rate of
D3-cortisol generation). Standard deviations (4.2 nmol/min) were taken from
previously published work using this technique (Andrew et al 2002). A sample size
of 9 has 80% power to detect a 22% change in enzyme activity to p<0.05. This is in
keeping with expected levels of change shown in previous in vitro and in vivo
experiments (>50% dowregulation in 11HSD1 activity following insulin
intervention).
In analysis of tracer and microdialysis data where repeated measures analysis
was undertaken, there were very few missing time points. Where a single time point
was missing an average value was calculated using preceding and following values.
For other data (not repeated measures), missing data points resulted in exclusion of
the case from paired comparison of that variable.
Data are presented as mean ± SEM. The time course of effects of insulin and
Intralipid on each measurement was examined by repeated measures ANOVA using
'placebo corrected' data (i.e. values at each time point for insulin or Intralipid were
subtracted from the values for saline infusion for each participant). Where ANOVA
identified effects of infusion, post-hoc paired t tests were performed to identify
differences in absolute values. This approach corrects for inter-subject variability in a
similar manner to a 'paired' repeated measures ANOVA, which cannot be performed
in Statistica, and is a method commonly used in crossover drug studies. It allows
investigation of acute changes in time course which would not be adequately
represented by paired comparisons of summary statistics (such as steady state values
or areas under curve).
To reduce the variance of kinetic parameters derived from deuterated-
steroid measurements, values were averaged for four measurements taken during
steady state in the final 30 minutes of the run-in period (180-210 min) and for three




The subjects were aged between 24 and 68 years (mean ± SEM, 41 ± 4.3),
with body mass index 19.7-30.2 kg/m2 (25.5 ± 1.2), Waist:Hip Ratio 0.8-1.1 (0.9 ±
0.03), and systolic blood pressure 106-168 mmHg (125 ±6.2).
4.3.2 Effects of infusions on plasma fuel substrates and insulin (Figure 4.2)
Following a light breakfast 90 minutes before the start of the study, insulin
and glucose concentrations returned to baseline values within 120 minutes. Insulin
infusion from 210 minutes resulted in raised plasma insulin, and reduced free fatty
acid levels, while plasma glucose levels were maintained as intended at ~5.0 mmol/1
with dextrose infusion. Intralipid infusion from 210 minutes resulted in raised plasma
triglyceride and free fatty acid levels and no change in plasma glucose or insulin
levels.
4.3.3 Whole body Cortisol metabolism
See Table 4.1 and Figure 4.3 and 4.4. Endogenous Cortisol production declined
during the study day, reflected in a rise in D4-cortisol enrichment, although the
downward trend in total unlabelled plasma Cortisol concentrations during D4-cortisol
infusions was not statistically significant. As previously described (Andrew et al
2002;Sandeep et al 2005), D4-Cortisol enrichment and D4-cortisol:D3-cortisol
ratios were in steady state at the end of the run-in period (ie values did not change
between 180 and 210 min). Thereafter, insulin and dextrose infusion increased the
rate of appearance of plasma D3-cortisol in plasma (reflected in lower D4-
cortisol:D3-Cortisol ratios) and tended to increase the appearance of endogenous
Cortisol (ANOVA p=0.07; reflected in lower D4-cortisol enrichment). Intralipid
infusion did not significantly alter any of the measurements of deuterated Cortisol
metabolism. Neither insulin not Intralipid infusion altered clearance rates of Cortisol
and D4-cortisol.
As previously described (Andrew et al 2002), urinary deuterated Cortisol
metabolite excretion does not reach steady state even during 7 hours of infusion, so
excretion rates were highest in the final hour of measurement (Table 4.1). However,
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Figure 4.2 Run-in Infusion
Effects of insulin and Intralipid infusion on plasma fuel substrates and
insulin Data are mean ± SEM for measurements during a 3.5 hour 'run-in'
tracer infusion followed by 3.5 infusion with saline (open diamonds, solid line),
insulin (filled squares, dotted line) or Intralipid (filled triangles, solid line).
Insulin infusion increased plasma insulin and suppressed plasma free fatty acid
concentrations (ANOVA, both p<0.01). Intralipid infusion increased plasma
triglycerides and free fatty acid concentrations (ANOVA, p<0.01) without
affecting plasma insulin. There were no differences in plasma


























Effects of insulin and Intralipid infusion on plasma Cortisol and
deuterated-cortisol enrichment Data are mean ± SEM for measurements
during a 3.5 hour 'run-in' tracer infusion followed by 3.5 infusion with saline
(open diamonds, solid line), insulin (filled squares, dotted line) or Intralipid
(filled triangles, solid line). Plasma Cortisol concentrations were not
significantly affected by insulin or Intralipid infusions. Statistical testing of
deuterated-cortisol metabolism was performed on kinetic parameters shown




Insulin and Lipid Regulation: 2H4-Cortisol kinetics
Sa ine Insulin Intralipid
Run-in Infusion Run-in Infusion Run-in Infusion
Plasma kinetics1
Total Cortisol (nM) 285 232 230 192 298 263
±52 ±33 ±39 ±32 ±57 ±49
Cortisol clearance 299 326 340 452 280 351
(ml/min) ±61 ±47 ±58 ± 122 ±52 ±96
D4-cortisol 400 406 521 643 410 409
clearance (ml/min) ±62 ±71 ±77 ±204 ±62 ±88
Rate of appearance 23.9 12.7 33.1 21.5 34.2 16.7
of endogenous ±4.8 ±4.5 ±7.0 ±6.5 ±8.5 ±7.2
Cortisol (nmol/min)
Rate of appearance 16.8 16.7 16.8 19.3 16.7 17.7
of D3-cortisol ±0.7 ± 1.1 ±0.7 ±0.8 ± 1.0 ± 1.3
(nmol/min) ***
Urine excretion2
D4-5a- 7.8 19.2 12.1 17.1 ± 12.3 25.0
tetrahydrocortisol ± 1.8 ±3.4 ±2.2 2.4 ±3.3 ±7.0
(ptg/h)
D4-5p- 8.6 19.0 13.9 15.7 ± 11.9 19.1
tetrahydrocortisol ± 1.7 ±3.8 ±2.3 3.5 ±2.2 ±3.4
(M-g/h)
D3-5p- 18.5 56.0 26.1 46.1 ± 23.6 49.8
tetrahydrocortisone ±3.0 ±6.9 ± 6.4 8.4 ±2.9 ±7.1
(Pg/h)
Sum of deuterated 54.3 162.4 82.3 137.5 ± 75.9 158.7
Cortisol metabolites ±7.2 ± 15.4 ± 13.7 15.2 ±8.1 ± 19.0
(jug/h)3
Data are mean ± SEM. Post-hoc comparisons were made only for variables for which
repeated measures ANOVA revealed effects of insulin or Intralipid infusion; differences
between saline infusion and insulin or Intralipid infusion were then tested by paired t tests.
***p<0.001
1 For plasma measurements, 'Run-in' data describe the mean of 4 measurements in the final
30 min of the 3.5 h D4-cortisol infusion before the introduction of saline, insulin or Intralipid
infusions. 'Infusion' data describe the mean of 3 measurements in the final 40 min of the 3.5
h during which saline, insulin and Intralipid were infused.
2 For urine measurements, 'Run-in' data describe measurements in the final 60 min of the 3.5
h D4-cortisol infusion before the introduction of saline, insulin or Intralipid infusions.
'Infusion' data describe measurements in the final 60 min of the 3.5 h during which saline,
insulin and Intralipid were infused.
3 Sum of urine metabolites = D4-5a-tetrahydrocortisol + D4-5P-tetrahydrocortisol + D3-5P-




























































Effects of acute hyperinsulinaemia and hyperlipidaeniia on rate of
appearance of plasma d3F after infusion of intravenous d4F. Data are
mean ± SEM for measurements of rate of appearance of d3F generated
from infused d4F in plasma of 9 participants before and during a 3.5 hour
infusion of saline (placebo), insulin (euglycaemic clamp) and lipid (20%
Intralipid) infusions. Steady state values were calculated from the mean
of four measurements between 180 and 210 min of D4-cortisol infusion.
The intervention values are taken as a mean of 3 measurements in the



















In Vivo 11HSD1 reductase vs dehydrogenase activity in adipose
tissue. Data are mean ± SEM for measurements from two microdialysis
cannulae within abdominal subcutaneous adipose tissue in 9
participants during the saline infusion phase alone. In one cannula,
3H-cortisone was infused and results are expressed as % conversion to
3H-cortisol (reductase activity, filled diamonds). In the other cannula,
3H-cortisol was infused and results are expressed as % conversion to
3H-cortisone (dehydrogenase activity, open diamonds). Reductase

























































Effects of insulin and Intralipid infusion on 11HSD1 activities in
subcutaneous adipose tissue. Results are from a 3.5 hour 'run-in' tracer
infusion followed by 3.5 infusion a) insulin or b) Intralipid. Data are mean
± SEM of 'placebo-corrected' values, i.e. the difference between the value
for each participant during saline infusion from the results during insulin
or Intralipid infusion. Absolute values during saline infusion are shown in
Figure 4.5a. Differences in conversion of 3H-cortisone to 3H-cortisol
(reductase activity) are in filled diamonds and differences in conversion of
3H-cortisol to 3H-cortisone are in open diamonds. By repeated measures
ANOVA, insulin altered reductase (p<0.05) but not dehydrogenase





4.3.4 Adipose 11HSD1 Activity (microdialysis)
During infusion of 3H-steroid, 11HSD1 reductase activity (conversion of cortisone to
Cortisol) exceeded dehydrogenase activity (conversion of Cortisol to cortisone) as
measured during the placebo infusion (Figure 4.5). During acute hyperinsulinaemia
in a euglycaemic clamp, reductase activity tended to fall during the first hour but
increased by 3.5 h (Figure 4.6, ANOVA p<0.05); dehydrogenase activity showed
similar changes which were not statistically significant. Intralipid infusion increased
both reductase (ANOVA p<0.01) and dehydrogenase activities (ANOVA p<0.03).
4.4 Discussion
These data demonstrate acute changes in Cortisol metabolism in healthy
humans in response to manipulation of fuel substrate availability. The increase in
Cortisol generation by 11HSD1 within peripheral tissues following the introduction
of hyperinsulinaemia or hyperlipidaemia suggests that adjustment of intracellular
Cortisol concentration may be a key component of the physiological response to
feeding.
Hyperinsulinaemia produced a highly statistically significant increase in whole-body
regeneration of D3-cortisol by 11HSD1. This observation is novel since previous in
vivo data are scarce, and those which rely upon measurement of urinary Cortisol
metabolites (Kerstens et al 2000) probably have insufficient sensitivity and
specificity to confirm or refute any effect of insulin on 11HSD1. In one previous
study D4-cortisol infusion was undertaken before and after hyperinsulinaemia (Basu
et al 2004), but no norm-insulinaemic control group was included, and effects on
splanchnic D3-cortisol production were not reported in detail, although there was a
small increase in D3-cortisol generation in the leg. Recent studies using
arteriovenous sampling have suggested that the major source of this extra-adrenal
production of Cortisol is the splanchnic circulation (Basu et al 2004), with
contributions from both liver and other visceral tissues (most likely visceral adipose
tissue)(Andrew et al 2005). Regeneration of Cortisol in non-splanchnic tissues has
been detected, for example in the leg (Basu et al 2005), where it may still play an
important role in determining local concentrations of Cortisol, even if substantial
Cortisol is not released into the circulation. In the current experiments, however, we
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found only a small effect of insulin locally within subcutaneous adipose tissue
(Figure 4.6). Investigations from our lab have previously shown that acute
hyperinsulinaemia induces a rapid, but temporary, fall in intra-adipose Cortisol
generation in lean but not obese men (Sandeep et al 2005). Here, the immediate fall
in 11HSD1 activity with hyperinsulinaemia was of smaller magnitude (Figure 4.6),
perhaps because the subjects had not fasted overnight in advance of the introduction
of hyperinsulinaemia. This was followed by a minor increase in 11HSD1 activity,
which is unlikely to contribute substantially to the increase in whole body D3-
cortisol generation. These observations suggest that the acute effects of insulin on
Cortisol regeneration occur in splanchnic rather than peripheral tissues. They do not
allow discrimination of effects in liver versus visceral adipose tissue, since it is quite
possible that regulation of 11HSD1 differs in subcutaneous versus visceral adipose
tissue, as illustrated by the lack of evidence for increased 11HSD1 in visceral
adipose tissue in obese subjects (Tomlinson et al 2002;Aldhahi et al 2004), despite
compelling evidence for increased enzyme expression in subcutaneous adipose tissue
(Rask et al 2001;Paulmyer-Lacroix et al 2002;Rask et al 2002;Wake et al
2003;Lindsay et al 2003;Engeli et al 2004;Kannisto et al 2004) (see chapter 3).
Intralipid infusion also influenced Cortisol metabolism. However, in contrast
with insulin, Intralipid induced substantial changes in subcutaneous adipose tissue
11HSD1 without altering systemic measurements of deuterated-cortisol metabolism.
There was no accompanying change in serum insulin concentrations. These
observations suggest a specific effect on 11HSD1 in extra-splanchnic tissues,
specifically subcutaneous rather than visceral adipose tissue, where fatty acid
turnover is high (Nielsen et al 2004) and the contribution of Cortisol regeneration to
the systemic circulation is probably low (Basu et al 2004). This may be mediated
directly by changes in fatty acid flux and concentration within the adipose cells but
this possibility has not been tested in vitro.
The mechanism of the effect of insulin and lipid infusion has not been tested
here. In vitro, insulin has been reported to down-regulate 11HSD1 expression and
activity in a number of cells, including hepatocytes, fibroblasts and adipose cells
(reviewed in (Tomlinson et al 2004b)). However, the in vitro effects may be
confounded by the influence of insulin on cellular differentiation in cell culture.
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Given the very acute effect of insulin observed in our previous study (Sandeep et al
2005) we suspected a post-transcriptional effect. Stewart and colleagues have
recently proposed that variations in supply of NADPH cofactor for 11HSD1 by the
enzyme hexose-6-phosphate dehydrogenase may limit the capacity for reductase
activity (regenerating Cortisol from cortisone), allowing a switch in favour of
dehydrogenase inactivation of Cortisol by 11HSD1 (Hewitt et al 2005). We did find
dehydrogenase activity within subcutaneous adipose tissue in vivo, as previously
reported ex vivo (Bujalska et al 2002a), but insertion of the microdialysis cannulae
causes significant local trauma so that it is possible that this reflects 11HSD1
favouring dehydrogenase activity only when it is dissociated from hexose-6-
phosphate dehydrogenase in damaged tissues. The magnitude of dehydrogenase
activity in adipose tissue in vivo might be assessed better with arteriovenous
sampling studies. Importantly, there was no evidence from our data that acute
regulation of 11HSD1 by insulin or Intralipid infusion is due to a switch in enzyme
direction (from reductase to dehydrogenase or vice versa) since enzyme activities
changed in parallel (Figure 4.6). Indeed, the time course of the Intralipid effect, being
maximal at the end of a 3.5 hour infusion, is consistent with transcriptional
regulation of availability of 11HSD1 protein, albeit that free fatty acid concentrations
were also rising steadily during the infusion (Figure 4.2).
Although the effects on regeneration of Cortisol were the most obvious in this
study, there may also be effects of insulin and lipids on other enzymes which
metabolise Cortisol. Basu et al. have reported that insulin increases splanchnic
Cortisol uptake (Basu et al 2004) while in the current study, in the face of increased
peripheral regeneration of Cortisol during hyperinsulinaemia there was no decrease in
Cortisol clearance rates. This suggests that insulin increases removal of Cortisol by
enzymes other than 11HSD1. The pathway responsible was not identified, since rates
of excretion of deuterated-cortisol metabolites in urine were not increased by insulin
(Table 4.1). Whether the increase in plasma Cortisol which follows ingestion of food
(Follenius et al 1982) has a component determined by altered Cortisol metabolism
has therefore not been resolved here.
These data have important implications in physiology and pathology.
Physiologically, they highlight that the rate of local regeneration of Cortisol is
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dynamic rather than static, and may allow acute control of glucocorticoid action over
and above alterations in the hypothalamic-pituitary-adrenal axis. In pathology, the
contrasting effects of insulin and lipid infusions on 11HSD1 in different tissues
highlights the capacity for tissue-specific regulation, which presumably underlies the
tissue-specific dysregulation which accompanies obesity (Rask et al 2001). Indeed,
we have shown that obese humans resist acute regulation of adipose 11HSD1 by
hyperinsulinaemia (Sandeep et al 2005), while obesity-prone strains of mice resist
down-regulation of adipose 11HSD1 by high fat feeding (Morton et al 2004b). The
current studies also illustrate that detailed dissection of Cortisol metabolism within
individual tissues in humans is now not only possible using these contemporary
tools, but likely to yield novel insights into glucocorticoid signaling in health and
disease.
4.5 Regulation of Adipose 11HSD1 by Insulin and Glucose in vitro
4.5.1 Introduction
To further assess the cellular mechanisms behind insulin and glucose regulation of
11HSD1 in adipocytes, in vitro studies in primary rat adipocytes were performed. I
assessed whether changes in 11HSD1 activity were associated with changes in
mRNA and/or changes in enzyme directionality, suggesting post transcriptional
modification via H6PDH as discussed above. In addition, the contribution of insulin
vs glucose as a regulator of 11HSD1 was assessed.
4.5.2 Methods
Primary adipocyte cultures were freshly prepared from adult male wistar rat
epididymal fat (see section 2.9). These were incubated in the presence or absence of
insulin and with varying concentrations of glucose, to form four groups; NILG= no
insulin, low glucose, NIHG= No insulin, high glucose, ILG= insulin, low glucose,
IHG= insulin, high glucose (see below):
11HSD1 reductase and dehydrogenase activities were assessed by separate
incubations with either 11-dehydrocorticosterone or corticosterone respectively,
assayed at 1 hour and 3.5 hours. Trizol was added to the remaining adipocytes,
mRNA extracted and quantified as discussed (section 2.9). Glucose uptake in the
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presence and absence of insulin was assessed (see section 2.9.3) All assays were
completed in duplicate. The whole experiment was repeated 6 times on different days
with different animals.
Insulin Cone Glucose Cone
No Insulin, Low Glucose (NILG) Nil 5.6mM
No Insulin, High Glucose (NIHG) Nil 22.4mM
Insulin, Low Glucose (ILG) 5nM 5.6mM
Insulin, High Glucose (IHG) 5nM 22.4mM
4.5.2.1 Statistics
All data were placebo corrected and assessed by ANOVA to determine
differences between groups and the individual role of insulin and glucose as a
determinant of change by post hoc analysis. Data was further analysed using
Students t-tests where discussed.
4.5.3 Results
4.5.3.1 Glucose Uptake
Insulin resulted in increased glucose uptake into adipocytes (p<0.05).
4.5.3.2 11HSD1 Enzyme Directionality
After lhr culture under basal conditions (no insulin, low glucose), reductase
activity is significantly greater than dehydrogenase (15.9 ± 1.1 vs 10.3 ± 0.9,
p<0.002, by students t-test), but no significant difference was found at 3.5hrs (19.0 ±
1.8 vs 18.1 ±2.1, p=0.34).
4.5.3.3 Insulin and Glucose Regulation
There were significant reductions in 11HSD1 reductase activity in the
presence of either insulin or high glucose at 1 hour. Insulin alone (without
hyperglycaemia) increased 11HSD1 reductase activity at 3.5hours (figure 4.7).There
was no difference in dehydrogenase activity between groups after at any time point
(figure 4.8) There was no differences in 11HSD1 mRNA expression after one hour,

































































No Insulin No Insulin Insulin Insulin
Figure 4.7
Acute changes in 11HSD1 reductase activity in primary rat
adipocytes with insulin and glucose after a) 1 hour of incubation and b)
3.5 hour of incubation. There were significant differences between all
groups (assessed by ANOVA) a) p=0.026 at lhr and b) p=0.025 at 3.5
hrs. Values shown are *=p<0.05, **p<0.01 when compared by t-test































































































































No Insulin No Insulin Insulin Insulin
Figure 4.8
Acute changes in adipose 11HSD1 dehydrogenase activity in primary
rat adipocyte cultures by insulin and glucose after a) lhour of
incubation and b) 3.5 hours of incubation. There was no significant
































































































No Insulin No Insulin Insulin Insulin
Figure 4.9
Acute changes in 11HSD1 mRNA in primary rat adipocytes with
insulin and glucose
There were no differences in mRNA expression at 1 hour. There were
significant differences in 11HSD1 mRNA between groups at 3.5 hours
(ANOVA p<0.00). Post hoc analysis showed that this could be attributed
to independent changes in both glucose (p=0.006) and insulin (p=0.04).
Values shown are **p<0.01 when compared by t-test with the control
group (No Insulin, Low Glucose).
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and hyperglycaemia together (Figure 4.9). In all groups combined, 11HSD1
reductase activity was associated with changes in mRNA after 3.5hrs (r=0.41,
p=0.005), but not after 1 hr (r=0.16, p=0.28).
4.5.4 Discussion
In vitro regulation of 1IHSD1 with insulin and glucose using rat adipocytes
in primary culture generally mimicked in vivo findings with an initial fall then
subsequent rise in 11HSD1 reductase activity at lhr and 3.5hrs respectively. The
initial reduction in 11HSD1 reductase activity was not associated with changes in
mRNA or enzyme directionality and appeared to be regulated by both insulin and
glucose; suggesting a post transcriptional process driven by 'glucose flux'. Increased
11HSD1 reductase activity at 3.5hrs occurred only in the low glucose/ high insulin
group, whereas increased mRNA was significantly increased in the high insulin/ high
glucose group only (i.e different groups). Across all samples there was, however, a
significant correlation between 11HSD1 activity and mRNA at 3.5 hours (p<0.005)
which was not seen at lhr. Although speculative, this suggests that transcriptional
regulation may have a role in mediating changes in enzyme activity at the later time
point, although clearly these preliminary studies are far from conclusive. In support
of in vivo findings, these studies do not suggest that the enzyme directionality is
acutely modulated by changes in cofactor availability. Had time permitted, I would
have assessed regulatory pathways in more detail, using inhibitors of transcription,
post transcriptional modification and insulin signalling and by in vitro manipulation
of H6PDH. In addition, I suggested earlier in this chapter that 11HSD1 up-regulation
in adipose with intravenous lipid followed a time course compatible with
transcriptional upregulation and would also have liked to have determined this using
in vitro studies or by mRNA analysis of human adipose biopsies.
Regulation of adipose 11HSD1 by lipid and dietary fat may alternatively be
mediated indirectly. One potential mechanism is through peroxisome proliferator-
activated receptors (PPARs) acting as cellular signallers of free fatty acid flux. The




REGULATION OF CORTISOL METABOLISM BY PPAR AGONISTS
5.1 Introduction
In chapter 4, we demonstrated regulation of Cortisol metabolism by two key
nutritional factors; insulin and lipid. Acute upregulation of adipose 11HSD1 by lipid
contrasts with reports of chronic down regulation with high fat feeding in animal
models (Morton et al 2004b). The exact mechanisms underlying nutritional
regulation of 11HSD1 remain unknown, but PPARs (as an important intracellular
lipid signaling pathway) may be implicated. PPAR agonists can downregulate
11HSD1 in adipose (PPAR-y) (Berger et al 2001) and liver (PPAR-a)
(Hermanowski-Vosatka et al 2000) respectively in animal and cell models, although
their effect in-vivo in humans is unknown. In addition, PPAR agonists are used
therapeutically; PPAR-y agonists (glitazones or thiazolidinediones) are adipose
insulin sensitizing agents used in type 2 diabetes whilst PPAR-a agonists (fibrates)
work within liver as lipid lowering drugs. It is an intriguing possibility that lowering
of intra-cellular Cortisol levels via 11HSD1 is a key mechanism by which PPAR
agonists mediate their downstream therapeutic effects thus limiting the metabolic
consequences of obesity. The main endogenous ligands for PPARs are free fatty
acids and PPAR activation may underlie regulation of 11HSD1 with high fat diet and
short term lipid exposure.
To assess this further, we assessed in vivo in 9 healthy male volunteers the
effects of short term PPAR agonists on whole body glucocorticoid turnover and
excretion, and tissue specific regulation of 11HSD1 within adipose and liver.
5.2 Methods (see chapter 2 and 4 for details)
Under ethical approval (Lothian regional ethics committee), 9 healthy men (BMI
20-35kg/m2) participated in a 3-phase double-blind crossover study comparing 1
week of oral rosiglitazone (Avandia 4 mg daily), or fenofibrate (Lipantil Micro 200
mg daily) with placebo (once daily tablet). The study order was randomised and
balanced. Phases were separated by 2-week washout. At the end of each treatment
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phase volunteers attended on two consecutive days for the following measurements
(discussed in detail in chapter 2):
i) 24 h urine collection for measurement of Cortisol metabolites by GCMS
(during the 24 hours prior to day 1)
ii) plasma lipids, insulin, glucose after overnight fast (day 1)
iii) 2H4-cortisol steady state infusion to measure 'whole-body' 11HSD1 activity
(day 1)
iv) infusion of 3H-cortisone by microdialysis into abdominal subcutaneous
adipose tissue to measure adipose 11HSD1 activity (day 1) and
v) oral 'cortisone to Cortisol' test to measure hepatic 11HSD1 activity (after
overnight dexamethasone suppression) (day 2).
5.2.1 Statistics
Sample size calculations were employed to calculate the participant number
required. The primary end point in this study was changes in 11HSD1 activity. The
sample size was calculated to give 80% power to detect differences in systemic,
hepatic and adipose 11-HSD activity of >20%, based on variance obtained with all of
these measurements in previous studies. This magnitude of change, equivalent to an
increase of plasma Cortisol from 300 nM to 360 nM is more than enough to be
biologically important, according to data from our large epidemiological studies
associating Cortisol with insulin resistance (Reynolds et al 2001).
In analysis of tracer and microdialysis data, when repeated measures analysis
was undertaken, there were very few missing time points. Where a single time point
was missing an average value was calculated using preceding and following values.
For other data (not repeated measures), missing data points resulted in exclusion of
the case from paired comparison of that variable.
Data are presented as mean ± SEM. To reduce the variance of kinetic
parameters derived from deuterated-steroid measurements, values were averaged for
five measurements taken during steady state in the final 45 minutes of the five hour
infusion to calculate plasma kinetics (255-300 min) (see chapter 2). Plasma data was
further analysed using paired t-tests to establish differences between placebo and
treatment phases. The time course of effects of fenofibrate and rosiglitazone
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treatment on adipose 11HSD1 (microdialysis) was examined by repeated measures
ANOVA using 'placebo corrected' data (i.e. values at each time point for fenofibrate
or rosiglitazone were subtracted from the values for the same time point in the
placebo phase for each participant). (Justification of this method of analysis is
discussed in section 4.2.3). Microdialysis values presented were calculated from area
under the curve (AUC) during the 5 hour period.
5.3 Results
5.3.1 Metabolic Effects; plasma markers (Table 5.1)
Treatment with fenofibrate resulted in lower plasma cholesterol, a trend to
lower serum triglycerides, but no significant changes in plasma glucose or fasting
insulin. Treatment with Rosiglitazone resulted in no significant changes in plasma
cholesterol, fasting triglycerides, fasting glucose, or fasting insulin.
5.3.2 Cortisol Tracer Kinetics (figure 5.1 and 5.2 and table 5.2)
As previously described (Andrew et al 2002;Sandeep et al 2005), plasma D4-
Cortisol enrichment and D4-cortisol:D3-Cortisol ratios were in steady state at the
end of the study. The rate of appearance of plasma D3-cortisol and Cortisol measured
over the steady state period did not change as a result of fenofibrate or rosiglitazone
treatment. The clearance rates for Cortisol appeared to be reduced by fenofibrate, but
not rosiglitazone. Clearance of D4-cortisol was not significantly changed by either
drug.
Tracer Cortisol metabolites were measured in the urine during the last hour of
the plasma tracer infusion. There were non significant reductions in 5a-reduced
urinary metabolites with fenofibrate but no significant changes in the urinary
excretion of tracer Cortisol metabolites with either fenofibrate or rosiglitazone.
5.3.3 Adipose 11HSD1
The PPARa agonist fenofibrate had no significant effect on adipose 11HSD1
reductase activity (AUC; 44.1 ±9.6 vs 49.3 ± 7.1 (placebo), p=0.13 by repeated
measures ANOVA). The PPARy agonist rosiglitazone however lowered reductase
activity significantly (AUC; 45.5 ± 6.6 vs 53.9 ±8.4 (placebo) p=0.01 by repeated
measures ANOVA) (figure 5.3).
129
Table 5.1
PPAR Regulation: Metabolic measurements and urinary metabolites
Placebo Fenofibrate Rosiglitazone
Plasma Measurements:
Fasting Glucose (mmol/1) 5.2 ±0.2 5.2 ±0.2 5.1 ±0.2
Fasting Insulin (mU/1) 7.7 ± 2.7 7.9 ±2.2 7.2 ± 1.3
Total Cholesterol (mmol/1) 4.6 ±0.3 4.2 ± 0.3* 4.8 ±0.3
Fasting Triglycerides (mmol/1) 1.4 ±0.3 1.0 ± 0.2a 1.6 ±0.3
Urinary Metabolite Excretion
over 24 hours (p.g/ 24 hours):
5a-THF 1057 ± 190 1171 ±334 1691 ± 334"
5p- THF 1851 ±367 1762 ±289 2301 ±616
5P-THE 2943 ± 620 3012 ±520 3601 ±972
Cortisol 85.1 ±12.9 80.6 ± 10.1 85.8 ± 16.2
Cortisone 120.4 ± 17.0 113.6 ± 13.2 131.1 ±22.9
Sum Total Metabolites 5850 ±997 5944 ±991 7594±1719
Urinary Ratios:
11HSD1 (THF+5aTHF/ THE) 1.1 ±0.1 0.99 ± 0.07* 2.1 ± 1.0
5a Reductase (5aTHF/F) 14.8 ±3.2 13.8 ±3.2 25.1 ±7.2
5P Reductase (5pTHF/F) 23.3 ±5.0 22.0 ±2.6 24.2 ± 3.9
5P Reductase (5pTHE/E) 24.9 ± 3.9 27.0 ± 3.5 24.4 ±4.2
11HSD2 (F/E) 0.72 ± 0.05 0.73 ± 0.04 0.65 ± 0.03
5a/ 5P Ratio (5aTHF/5PTHF) 0.79 ± 0.2 0.68 ±0.16 2.2 ± 1.5
Data are mean ± SEM. *p<0.05, ap<0.1 by paired Student's t tests compared with
placebo. THF= tetrahydro-cortisol, THE= tetrahydro-cortisone, F=cortisol, E=
cortisone. Sum Total Metabolites= 5p-THF + 5a-THF +5P-THE
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Table 5.2
PPAR Regulation: 2H4-Cortisol kinetics
Placebo Fenofibrate Rosiglitazone
Steady state plasma calculations:
F Clearance (L/ min) 0.19 ±0.02 0.17 ±0.02* 0.21 ±0.03
d4F Clearance (L/ min) 0.37 ± 0.06 0.35 ± 0.08 0.43 ± 0.09
Ra F (nmol/min) 50.7 ± 14.4 54.8 ± 16.4 67.01 ± 16.0
Ra d3F (nmol/min) 16.3 ± 1.6 16.07 ±2.6 16.6 ±2.8
Urinary labeled steroid excretion
in steady state (t 240-300)
(nmol/min):
D4-cortisol 0.12 ±0.02 0.09 ± 0.02 0.10 ±0.02
D4-5a-tetrahydrocorti sol 1.33 ±0.29 1.03 ±0.21 0.91 ±0.14
D4-5P- tetrahydrocorti sol 1.57±0.24 1.54 ±0.21 1.42 ±0.19
D3-cortisone 0.21 ±0.01 0.18 ±0.02 0.22 ±0.01
D3-5P-tetrahydrocortisone 1.95 ±0.14 2.04 ±0.3 2.05 ± 0.34
D3-cortisol 0.27 ±0.07 0.23 ±0.05 0.18 ±0.02
D3-5a-tetrahydrocortisol 1.05±0.19 0.85 ±0.17 0.75 ±0.11
D3 -5P-tetrahydrocorti sol 1.14 ± 0.15 1.17 ± 0.15 1.01 ±0.11
D3-THFs/D4-THFs 0.77 ± 0.02 0.80 ±0.03 0.77 ± 0.03
D3-THE/D4-THFs 0.76 ±0.11 0.85 ±0.14 0.84 ±0.07
D3-THFs/D3-THE 1.12 ± 0.11 1.1 ±0.13 0.97 ± 0.08
Data are mean ± SEM. *p<0.05, ap<0.1 by paired Student's t tests compared with
placebo. For plasma measurements, kinetics were calculated using the mean of all
measurements between 255 and 300 minutes of the 5 h D4-cortisol tracer infusion.






Effects of PPAR agonists on in vivo Cortisol kinetics. Data are mean
SEM. for measurements during a 5 hour tracer infusion followed
treatment with PPAR agonists/ placebo. Placebo (open diamonds, solid
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Figure 5.2
Effects of PPAR agonists on in vivo Cortisol urinary tracer metabolite
excretion. Data are mean ± SEM. for measurements during a 5 hour
tracer infusion followed treatment with PPAR agonists/ placebo. Placebo
(open diamonds, solid line), fenofibrate (filled squares, dotted line) or
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Figure 5.3
Effects of PPAR agonists on 11HSD1 reductase activity in adipose
and liver
Data are mean ± SEM. Adipose 11HSD1 reductase activity was reduced
by rosiglitazone (ANOVA,p<0.01), but not fenofibrate. Adipose 11HSD1
activity measured by hourly conversion of 3H-cortisone using in vivo
microdialysis. Liver 11HSD1 activity was assessed by conversion of oral
cortisone to plasma Cortisol. No significant difference seen with
Rosiglitazone or Fenofibrate.
134
5.3.4 Liver 11HSD1; oral cortisone to Cortisol test
Appearance of Cortisol in the plasma following oral cortisone was analysed
and kinetic parameters calculated using Kinetica™ software (Innaphase Corporation,
PA, USA) (figure 5.3). Neither PPARa agonist fenofibrate nor PPARy agonist
rosiglitazone had a significant effect on any of the kinetic parameters measured (Rate
of appearance, area under curve, maximum Cortisol concentration (CMax),
elimination constant (Kel), half life or clearance rates (CI)). There were trends
towards lower clearance parameters with Rosiglitazone (higher Kel; 6.5 ± 2.3 vs 5.5
±2.9, p=0.13 and reduced CI; 116.4 ±3.93 vs 176.19 ± 15.54, p=0.17)
5.3.5 Urinary Cortisol Metabolites (24 hour urine collection) (table 5.1)
In urine collected over the 24 hour period immediately prior to admission to
the research facility, there was a trend towards higher 5a-THF production with
rosiglitazone but no other difference in the total excretion of urinary Cortisol (tetra-
hydro) metabolites or excretion of any other individual metabolite (all p>0.1). There
was no difference in the relative 5a and 5P reduction of Cortisol as assessed by
Ulick's A-ring reduction quotients (section 2.6.3) but the ratio of endogenous THFs
to THE (indicative of total 11HSD1 activity) was lowered by fenofibrate (table 5.1).
5.4 Discussion
Cortisol generation within adipose tissue may be important in mediating
adipogenesis, insulin resistance, dyslipidaemia and hypertension as is demonstrated
by the obese and dysmetabolic phenotype of adipose specific 11HSD1
overexpressing mice (Masuzaki et al 2001). Further, obese humans have elevated
11HSD1 within sub-cutaneous adipose which correlates well with the degree of
insulin resistance (Lindsay et al 2003). Rosiglitazone is an insulin sensitising agent
used in the treatment of type 2 diabetes. Previous in vitro studies demonstrate
reduced 11HSD1 following short term PPARy agonist therapy (Hermanowski-
Vosatka et al 2000). Here, we demonstrate a small but significant reduction in
11HSD1 activity in vivo in subcutaneous adipose tissue in man with oral PPARy
agonists. We speculate that lowering of adipose 11HSD activity (and intra-adipose
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Cortisol) may potentially contribute to the action of thiazolidinediones, altering
transcription of insulin sensitising genes via glucocorticoid receptors.
PPARy is an important mediator of cellular response to dietary fat via
circulating free fatty acids (FFAs) and a major regulator of adipogenesis. High fat
feeding in rodents results in reduced adipose 11HSD1 and obesity prone rodent
strains resist downregulation of adipose 11HSD1 by dietary fat (Morton et al
2004a;Morton et al 2004b). The underlying mechanism is unclear but we can now
speculate that changes in 11HSD1 may be secondary to PPARy activation via FFAs.
Reduced Cortisol generation during periods of increased free fatty acid flux may
impact on lipolytic response and limit adipogenesis.
In this study we saw no change in whole body plasma glucocorticoid turnover
with PPARy activation. Plasma tracer measurements give a net effect of whole body
change, and it is possible that decreased 11HSD1 in adipose is being balanced by
upregulation in another tissue (e.g. liver) with no measurable change in net turnover.
Alternatively, this may be because small changes in sub-cutaneous adipose 11HSD1
do not significantly contribute to the circulating glucocorticoid pool. Indeed, Basu et
al (Basu et al 2004) showed that splanchnic Cortisol generation accounts for the
majority of whole body regeneration, suggesting that subcutaneous generation may
be important locally but not systemically.
11HSD1 within liver regulate keys gluconeogenic enzymes such as PEPCK.
Overexpression of 11HSD1 in the liver under an ApoE promoter results in fatty liver,
dyslipidaemia, mild insulin resistance and hypertension which is thought to be
mediated by increased angiotensinogen expression (Paterson et al 2004). PPARa is
found mainly within liver and is the target for fenofibrate, a therapeutic lipid
lowering agent, although downstream targets of the drug are poorly understood.
Fenofibrate lowers liver 11HSD1 in animal studies (Berger et al 2001) and we
speculated that this may contribute to its therapeutic action. In this in vivo study in
man, fenofibrate resulted in reduced clearance of endogenous Cortisol but no change
in plasma tracer turnover or clearance kinetics. The impact on 11HSD1 specifically
within the liver remains unclear. Although no major effect was seen on conversion of
oral cortisone to plasma Cortisol, the urinary ratio of THFs: THE was decreased. This
might be indicative of either reduced liver 11HSD1 or altered hepatic A-ring
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reductase activities. 5a metabolites did appear to be reduced by fenofibrate during
tracer infusion, although this did not reach significance. Decreased 5a-reductase
activity could ceratianly explain both these findings i.e. changes in urinary ratios and
reduced Cortisol clearance observed with fenofibrate treatment.
These studies suggest that acute regulation of Cortisol generation, particularly
within adipose, may have important physiological and therapeutic consequences.
However, the magnitude of these changes, in the absence of systemic differences in
11HSD1, is at the threshold of sensitivity of the techniques we are using. 11HSD1 is
emerging as a potentially important regulator of cellular response to dietary fat and
FFA flux. Alterations in tissue Cortisol levels via 11HSD1 may mediate important
downstream effects via manipulation of GR-sensitive gene targets within tissues
even without measurable impact on circulating glucocorticoid levels, as seen here.
Whether PPAR agonists truly require glucocorticoid signalling for their
action is however unclear. We have set up further studies to test this hypothesis,
looking at the effects of PPARy agonists in the presence and absence of
glucocorticoid receptor inhibitor (RU486). This will determine the role of
glucocorticoid signalling in the therapeutic action of PPAR agonists and also, by
assessment of mRNAs in adipose biopsies, allow determination of potential
downstream glucocorticoid targets mediating insulin sensitivity.
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Chapter 6
ADIPOSE SEX STEROID METABOLISM AS A DETERMINANT OF FAT
ACCUMULATION AND DISTRIBUTION
6.1 Introduction
In addition to the effect of glucocorticoids, sex steroids (androgens and
estrogens) also play an important role in determining body fat distribution. Central
adiposity, which is associated with increased cardiovascular risk, is thought to reflect
a predominance of androgens over estrogens (Bjorntorp 1997) as is evident from
predisposition to 'central' ('abdominal' or 'android') obesity in men and 'peripheral'
('gynoid') obesity in women. As with glucocorticoids, sex steroid action in adipose
is mediated by intra-cellular receptors for oestrogens (ERa and ERP)(Pedersen et al
2001 ;Dieudonne et al 2004), and androgens (AR). Aromatase and 5a-reductase
enzymes also function in a similar manner to 11HSD1 controlling pre-receptor ligand
availability for oestrogen and androgen receptors respectively (section 1.13).
In addition, the aldo-ketoreductase enzymes (AKRs) are now emerging as
potentially important regulators of progesterone, glucocorticoid and most
significantly androgen metabolism in adipose. Several isoforms have been studied in
human sub-cutaneous and omental adipose tissue. AKR1C type 1 (20ct-HSD) in
omental adipose tissue has been related to the degree of central obesity (Blanchette et
al 2005). Conversely, AKR1C3 (i.e. 17P-HSD5, the predominant 17P-HSD isozyme
in human adipose tissue) (Quinkler et al 2004) in subcutaneous rather than visceral
adipose tissue has been associated with generalised obesity (Quinkler et al 2004).
The significance of other human 17P-HSD isozymes is less clear: types 1-3 have not
been detected by all investigators (Corbould et al 1998;Quinkler et al 2004) and type
4 is present at lower abundance than type 5 (Quinkler et al 2004). AKR1C2 (3a-
HSD3) is also expressed in human adipose tissue but its role is uncertain (Quinkler et
al 2004) Adipose sex steroid metabolizing enzymes are summarized in schematic -
figure 1.5
Against this background, we have extended our previous studies of 11HSD1
in adipose tissue from healthy male and female adults with well-characterised body
fat distribution as discussed in chapter 3 (Rask et al 2001;Westerbacka et al 2003),
138
by examining mRNAs in these biopsies for sex steroid receptors (ERa, AR) and
enzymes dictating local activation of estrogens (aromatase), and androgens (5a-
reductase type 1). Further, we assessed for the presence of the 4 AKR isoforms in
adipose and quantified mRNA for the 2 predominant aldoketoreductase isoforms
(AKR1C2 and AKR1C3). To understand likely pathways of dysregulation of these
enzymes and receptors, and their likely impact on metabolic complications of
obesity, we also measured mRNAs for potential regulating factors (IL-1, 1L-6, TNF-




We analysed adipose tissue from two previously described cohorts: 14 men
and 13 women from Sweden (Rask et al 2001;Rask et al 2002;Wake et al 2003) and
18 men from Finland (Westerbacka et al 2003) (see sections 3.3.2 and 3.4.2 for
details of recruitment, clinical measurements, and procedures ).
6.2.2 Adipose Biopsy analysis
mRNA was extracted and processed as described in chapter 2. Transcript
level quantification was performed with specific Real Time PCR primer-probe sets
using the ABI PRISM 7700/ 7900 Sequence Detection System for Aromatase, 5a-
Reductase Type 1, AKR1C2, AKR1C3, ER-a, AR, IL-6, IL-la, TNF-a , LPL,
HSL, PPAR-y, Angiotensinogen, Leptin , Resistin, Adiponectin, AKR1C2 and
AKR1C3.
5a-reductase type 2 is typically found in cutaneous and genital tissue and has
a major role in development of an external masculinised phenotype. The type 1
enzyme, however, is found in many peripheral tissue and has a role in both
glucocorticoid and androgen metabolism. We therefore assessed for the presence of
the type 1, but not the type 2, enzyme. There are two estrogen receptors in adipose
(ERa and ERP). We did not assess ERP because, although it is present in adipose,
ERa is by far the predominant isoform and is thought to be the major receptor
dictating adipose oestrogenic effects (Dieudonne et al 2004).
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PCR was also performed using specific primers (below) for the 4 human
isoforms of AKR1C in pooled cDNA from each cohort (see section 2.5.2.3) at 20,30
and 40 cycles and run on a 1.25% agarose/ TBE gel for analysis.
6.2.3 Statistics
T-tests were performed to examine differences between genders and cohorts.
Relationships between biopsy measurements and anthropometric parameters in the
combined cohorts were examined by multiple regression analysis and corrected for
cohort and gender (both coded as 0 or 1). Real time PCR on each cohort was
performed in separate batches, using a relative standard curve of diluted cDNA
pooled from within each cohort, so that, although cohorts may differ in apparent
absolute mRNA levels, this may reflect a systematic difference in the standard curves
in the two cohorts rather than selective differences in these mRNAs. For this reason
multiple regression analysis adjusted for differences between cohorts where
appropriate. Inter-relationships between mRNAs were examined using multiple
regression analysis to correct for cohort, gender (both coded as 0 or 1), and BMI.
Results are presented as standardised beta-coefficients (r).
6.3 Results
6.3.1 Gender differences and other potential confounders
Participants were aged 54.5± 2.0 years (range 33-73) with BMI 25.9 ± 0.6
kg/m2 (range 20.7- 32.0) in the Swedish cohort and 41.8± 2.5 years (range 22- 57)
with BMI 26.4 ± 0.9 kg/m2 (range 20.6- 35.6) in the Finnish cohort. The cohorts
differed in age, percentage fat (29.0± 0.06 Sweden vs 21.5+ 1.37 Finland, p<0.01)
and waistihip ratio (0.90± 0.01 Sweden vs 0.97± 0.02 Finland, p<0.01).
Comparisons by gender and between cohorts is shown in Table 6.1. In the
Swedish cohort, aromatase, 5a-reductase type 1, AR, FPF and HSF mRNAs were
higher in men than women. Feptin and angiotensinogen mRNAs were higher in
women. There were no gender differences in expression of other mRNAs. As
discussed in section 6.2.3, although cohorts differed in apparent absolute mRNA
levels for FPF and HSF, this may reflect a systematic difference in the realtime PCR
standard curves in the two cohorts rather than selective differences in these mRNAs.
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6.3.2. Presence of Aldoketoreductase
AKR1C2 was the predominant isoform in subcutaneous human adipose,
followed by AKR1C3 and then AKR1C1 (20a(3ct)-HSD). AKR1C4 mRNA was not
detected (figure 6.1). Real Time PCR quantification of the 2 predominant isoforms
revealed ~32-fold higher AKR1C2 than AKR1C3 transcript expression (23.5± 0.16
vs 28.5± 0.23 cycles), with both being higher in abundance than mRNA for
aromatase (35.9± 0.17 cycles).
6.3.3. Predictors of body fat and its distribution
See Table 6.1 and figure 6.2. To examine associations with obesity, multiple
regression analysis was employed with adjustment for potential confounding by
gender and cohort. BMI was positively associated with adipose aromatase mRNA.
Percentage body fat showed a strong trend for an association with aromatase mRNA.
Neither 5a-reductase type 1, ERa nor AR mRNAs were associated with generalised
obesity.
In contrast, central adiposity (measured by waist:hip ratio) was not correlated
with aromatase mRNA in subcutaneous adipose tissue. In addition, central obesity
was associated with higher mRNA levels for both AKR1C2 and AKR1C3. There
was no overall relationship between waist:hip ratio and any other mRNAs.
6.3.4. Relationships between determinants of steroid hormone action and their
potential regulators and target genes
Inter-relationships between mRNAs for steroid metabolising enzymes and
their receptors were sought by multiple regression adjusting for gender, cohort and
BMI. Results are shown in Table 6.2. Broadly, there were rather few correlations
observed, although AKR1C3 and AKR1C2 isoform mRNAs correlated with each
other.
Inflammatory cytokine expression (IL-la, IL-6, TNF-a) was not related to body fat
or its distribution (Table 6.1). To examine relationships between determinants of
steroid hormone action and inflammatory cytokines, adipokines and key metabolic
genes in adipose, multiple regression analyses were performed with adjustment for
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Aldoketoreductase Isoforms in Human Adipose
PCR results using specific primers for the four human 3alpha HSD genes,
AKR1C1 (h20a (3a)-HSD), AKR1C2 (type 3, 3a-HSD), AKR1C3 (type
2, 3a-HSD), AKR1C4 (type 1, h3a-HSD). All PCR products are 500bp.
Subcutaneous adipose cDNA was pooled from both Swedish and Finnish
cohorts and PCR products generated at 40 cycles. A single RT- control is
shown, but both water and RT- controls were assessed for all genes (all
negative).
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Figure 62
Associations of obesity with mRNA for (a) aromatase and (b)
AKR1C2 in subcutaneous adipose tissue
Results are shown for filled diamonds=Swedish men, filled
triangles=Swedish women, and crosses=Finnish men. Correlations are
shown in Table 1.
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positively correlated with IL-6 and TNF-a mRNA. IL-la was associated with 5a-
reductase 1 mRNA.
Regarding metabolic genes in adipose tissue, findings were rather diverse.
HSL and leptin mRNAs correlated with ERa mRNA. 5a-Reductase 1 mRNA
correlated positively with LPL and PPARy mRNAs. Neither resistin nor adiponectin
mRNAs correlated with any mRNAs for determinants of steroid signaling.
6.4 Discussion
These studies address the associations of variations in sex steroid hormone
signalling in subcutaneous adipose tissue with body fat accumulation and
distribution, and intra-adipose gene expression, in humans. Subjects represented a
common range of body fat mass, rather than being morbidly obese or lean. The major
findings were that increasing generalised obesity is associated with increased mRNA
for the estrogen-generating enzyme aromatase. Conversely, central fat distribution
(as measured by waist/hip ratio) was associated with no difference in aromatase, but
increased AKR1C2 and AKR1C3
Genetic deficiency of aromatase in human and animal models results in
central obesity (Jones et al 2000;Simpson 2000a;Jones et al 2001) while a gain of
function mutation in aromatase causes a female body habitus and gynaecomastia in a
male patient (Shozu et al 2003). In a previous smaller study, aromatase mRNA in
omental adipose tissue was inversely correlated with BMI, while aromatase mRNA
in subcutaneous adipose was not related to obesity, but the latter observation was
restricted to just 8 participants (Corbould et al 2002). Our findings suggest that
increased subcutaneous adipose aromatase, generating more local ER ligands and
consuming potential AR ligands, may favour peripheral fat deposition rather than
intra-abdominal deposition in subjects who gain weight. This may underlie raised
plasma estrogen levels in idiopathic obesity (Zumoff 1982).
It is more difficult to deduce the consequences of alterations in
aldoketoreductases in adipose tissue. The four human AKR1C isoforms share
extensive sequence homology but have varying degrees of 3, 17 and 20 keto-
reductase/dehydrogenase activity, and tissue specific distributions. AKR1C4 is
almost entirely liver specific and probably responsible for much of the 3a reduction
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of glucocorticoids and other 5a- and 5[3-reduced pregnene steroids (Penning et al
2000) so it is unsurprising that we did not detect its mRNA in human adipose.
However, confirming a previous report (Quinkler et al 2004), we found high
expression of AKR1C2 and AKR1C3 in human sub-cutaneous adipose. These
isoforms were expressed at higher levels than the AKR1C1 isoform, which has
recently been associated with obesity by another group (Blanchette et al 2005) but
has a primary role in 20a-reduction of progesterone. Extrapolation from their roles in
prostate suggests that the type 2 and 3 isoforms can increase AR ligands within
adipose tissue, since they convert 3a-androstanediol to 5a-DHT (AKR1C2) and
androstenedione to testosterone (AKR1C3) (Figure 1.5). However, these isoforms
can also catalyse 3a-reduction and inactivation of 5a-DHT. Previous studies of their
net catalytic activity in human adipose tissue have been inconsistent, with reports of
predominant androgen inactivation (Blouin et al 2003) and activation (Quinkler et al
2004). This merits further investigation, including measurements of steroid
interconversions in vivo, but our results are consistent with the hypothesis that
increased adipose AKR1C3 may increase androgen action (acting as 17P-HSD type 5
- Figure 1.5) and hence promote central obesity, but that this effect may be offset by
increased androgen inactivation by AKR1C2 (acting as 3a-HSD type 3 - Figure 1.5).
Previous in vitro and in vivo studies have demonstrated the presence of 5a-
reductase activity (but not mRNA) in adipose tissue (Killinger et al 1990). We have
demonstrated that adipose 5a-reductase activity can be attributed to the type 1
isozyme but its expression was not associated with generalised or central adiposity.
However, 5a-reductase type 1 mRNA was associated with LPL and PPARy mRNAs,
which might be explained by effects of 5a-reduced androgens on AR. 5a-Reduced
metabolites of glucocorticoids acting through GR (Mclnnes et al 2004) may also
contribute to these associations. It is possible that these results, particularly in the
inter-analysis of adipose mRNAs, may be subject to bias from multiple statistical
testing. Bonferroni corrections were not used here, but we accept that results with
borderline significance should be interpreted with caution. We have therefore
concentrated in our discussion on findings that were consistently found in all cohorts
or with highly significant p values suggesting a 'real' effect.
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In the analysis of inter-relationships between adipose tissue mRNAs we
found that inflammatory cytokine mRNAs were associated with some of the
determinants of sex steroid action (5a-reductase 1 and ERa mRNAs), independently
of obesity and gender. Although in vitro regulation of these cytokine genes has not
been reported in detail in human adipose, and the likely direction of causality
remains uncertain, it is notable that estrogen may modulate the expression of several
pro-inflammatory cytokines and serum levels of IL-6 are decreased in ERa knockout
mice (Lindberg et al 2001). Estrogen may also regulate leptin mRNA and production
(Ainslie et al 2001;Okura et al 2003) and leptin regulates proinflammatory immune
responses to inflammatory stimuli (Loffreda et al 1998).
We also correlated mRNAs for gene products involved in steroid signalling
with some of those regulating adipose metabolic function. Androgens and estrogens
regulate lipolysis, adipogenesis and leptin in vitro (Ringold et al 1986;Machinal-
Quelin et al 2002;Anderson et al 2002;Dang et al 2002;Bourguiba et al 2003;Palin et
al 2003). The principal correlations were, again, with ERa and 5a-reductase 1 (Table
6.3). However, the genes that were measurably different in obese subjects (ie
aromatase, AKR1C2 and 3) were not correlated with gene products determining
adipose metabolism. Further, the striking effects of estrogen on angiotensinogen
mRNA in animal models (Stavreus-Evers et al 2001) were not reflected in these
human studies. Thus, the local impact within the adipose tissue of altered steroid
metabolism in obesity remains unproven.
Although it has been speculated that it is intra-abdominal adipose where
steroid signalling is most influential, and it is possible that different regulation of
enzymes occurs in the visceral bed, it is not possible to obtain biopsies of this tissue
under non-stressed non-anaesthetised conditions and so our studies have been
restricted to subcutaneous adipose tissue. It may be that quite different dysregulation
of steroid signalling occurs in intra-abdominal adipose tissue (Montague et al 1998),
as suggested in previous studies (Corbould et al 2002;Quinkler et al 2004). Clearly,
correlations within samples in cross-sectional studies cannot test causality, but they
provide important circumstantial evidence for the likely pathways in which
alterations in steroid signalling are involved. Further studies of protein levels and
using enzyme inhibitors will ultimately be required.
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In conclusion, these data suggest that there is dysregulation of enzymes
regulating the availability of ligands for ER (aromatase) and AR (AKR1C2 and 3) in
subcutaneous adipose tissue in human obesity. These may interact to determine body
fat distribution during weight gain. It is clear that studying circulating hormone
levels is no longer sufficient, and exciting insights are to be gained from
understanding the complex intracrinology of steroid action in adipose tissue. The





Obesity is the fastest growing health threat to face the Western World. The
specific role of adipose tissue as a generator of hormonal factors and cytokines with
both local and distal action is emerging and adipose endocrinology may play a major
role in the pathogenesis of the metabolic syndrome. Glucocorticoid excess, as in
Cushing's syndrome, causes central obesity, hypertension, insulin resistance and
dyslipidaemia. Local generation of glucocorticoids within tissues may be mediated
by 11HSD1 and both obesity prone animal models and transgenic manipulation of
11HSD1 suggested a key role in obesity and the associated dysmetabolic phenotype.
On this background, this thesis assessed the impact of local steroid generation
particularly within adipose in human obesity, and aimed to determine key regulators
and downstream targets.
These studies support previous animal work and demonstrate transcriptional
up-regulation of 11HSD1 in sub-cutaneous adipose tissue in human obesity. This
finding was confirmed in men and women and across different populations (in
Finland, Sweden and America), but was not altered by ethnicity, as determined in
American Pima Indians. Adipose 11HSD1 was clearly associated with adiposity
(generalised rather than visceral fat accumulation) and downstream features of the
metabolic syndrome, notably insulin resistance. We could not, however, demonstrate
a clear relationship between 11HSD1 and potential downstream glucocorticoid target
genes. Also, glucocorticoid receptor mRNA was downregulated in subcutaneous
adipose in obesity which may attenuate the downstream impact of active generated
steroid. These studies however simply assessed relationships by cross sectional
analysis of mRNAs. Determination of downstream impact would be best assessed by
modulation of 11HSD1 activity in dynamic in vivo studies.
11HSD1 is altered in a tissue specific manner in generalised idiopathic
obesity (increased in adipose and reduced in liver), suggesting that the enzyme is
being dysregulated at a local level. Potential regulating factors that are altered in
obesity include cytokines and nutritional signals, and both animal and in vitro studies
suggest that 11HSD1 is involved in the adaptive response to nutrition.We assessed
regulation in healthy male volunteers to metabolic signals demonstrating adipose
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specific changes in glucocorticoid generation secondary to acute hyperlipidaemia,
hyperinsulinaemia and short term PPAR agonists. Changes in local Cortisol
production may regulate key adipocyte functions, such as control of lipolysis,
adipogenesis and adipokine production. Adipose 11HSD1 may be an important
mediator of cellular responses to dietary fat and carbohydrate intake, although
whether these regulatory mechanisms are altered in obesity remains to be
determined. Further, alterations in tissue glucocorticoids may contribute to the
therapeutic action of PPAR agonists, used clinically as insulin sensitizing and lipid
lowering agents. Increased systemic Cortisol generation was demonstrated with
hyperinsulinaemia but could not be fully explained by local changes in subcutaneous
adipose 11HSD1. It is likely that this is due to increased 11HSD1 in another tissue
source such as visceral adipose tissue or liver. Increased peripheral generation of
Cortisol by hyperinsulinaemia may contribute to the phenomenon of post prandial
hypercortisolaemia, previously attributed to changes in hypothalamic pituitary
signaling.
Our in vivo studies demonstrate changes in local Cortisol generation without
corresponding impact on circulating Cortisol levels, suggesting that subcutaneous
adipose has a limited role in systemic glucocorticoid generation. Indeed Basu et al
and Andrew et al (Basu et al 2004;Andrew et al 2005) suggested that splanchnic,
rather than subcutaneous adipose may be the greater source of whole body cortisone
to Cortisol conversion. Sub-cutaneous adipose 11HSD1 may however retain a very
important local role mediating key adipocyte processes through intra-cellular
regulation of downstream glucocorticoid target genes.
Although the main focus of this thesis was glucocorticoid metabolism in
obesity, we briefly extended our studies to determine whether abnormalities were
also found in key enzymes controlling sex steroid generation within adipose. The
role of testosterone and estrogen in determining adipose tissue distribution is evident
by gender differences, but circulating sex steroid levels do not consistently determine
adipose deposition in population studies. We therefore speculated that tissue steroid
metabolism may have a key role.
These studies demonstrate that mRNA for testosterone metabolizing
enzymes, AKR1C2 and 3 was associated with central adiposity, whilst mRNA for
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the estrogen generating enzyme aromatase was associated with generalised obesity.
11HSD1 is emerging as a key mediator of local glucocorticoid response. We now
speculate that there is a very similar role for these key sex steroid metabolizing
enzymes in determining local androgen and eostrogen action, although further
dynamic and functional studies are undoubtedly required.
To conclude, these studies implicate dysregulation of 11HSD1 transcription
in the pathogenesis of human obesity and the metabolic syndrome although the
downstream impact of enzyme dysregulation remains unclear. These studies have
identified some key enzyme regulators in vivo in humans. Understanding normal
enzyme regulation in humans will allow further studies to dissect the basis of
dysregulation in obesity. The widespread metabolic benefits of transgenic
manipulation and enzyme inhibition in rodents suggest an important role for
11HSD1. Inhibition of adipose 11HSD1 remains an intriguing target for the
treatment of human obesity and its metabolic complications but its physiological
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